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Discovering Novel Feedback and Crosstalk Mechanisms in Cellular Signaling Pathways 
 
Abstract 
 
Multiple signaling pathways control cellular response to environmental cues such as 
nutrients, growth factors and stress.  Interpretation of these cues requires coordinated regulation 
of intracellular signaling pathways.  Our attempt to understand how cells coordinate different 
signaling pathways led to the discovery of two crosstalk mechanisms between different signaling 
cascades.   
We found that PI3K-AKT signaling reduces EGFR signaling to the parallel ERK-MAPK 
pathway by enhancing EGF induced EGFR degradation.  At the molecular level AKT activates 
PIKfyve to facilitate EGFR trafficking from early endosomes to the lysosomes. 
 Using a mass spectrometry based approach we also found growth factor signaling by 
EGF inhibits stress response.  In particular, inhibiting RSK signaling downstream of EGF 
increased the activity of stress activated kinases p38, MSK2 and ERK5.  We propose that when 
growth factors are present active RSK phosphorylates and inhibits a master regulator of stress 
response MEKK3, which leads to termination of MEKK3 signaling to downstream kinases. 
 Our unbiased phosphoproteomic approach also lead to identification of many ERK and 
RSK substrates that will help us explain how growth factor signaling regulates a wide variety of 
biological processes. 
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INTRODUCTION 
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Cell Signaling Basics 
Biological systems rely on proper reception and efficient interpretation of extracellular 
and intracellular cues to thrive. Cells monitor the availability of nutrients; energy; growth 
factors; connections with other cells and the extracellular matrix. Stress factors such as DNA 
damage, hyper osmolarity and inflammation are also monitored by the cell to make adaptive 
changes.  In response to these changes cells decide to grow, proliferate, migrate, differentiate, 
change their metabolism or undergo cell death (Figure 1.1).   
Misperception or misinterpretation of extracellular and intracellular signals leads to 
disruption of cellular and organismal homeostasis and can be detrimental. Therefore, living 
organisms employ intricate signaling pathways to ensure proper regulation of biological 
processes by regulating the functions of each protein in the cell.  Such regulation occurs at the 
transcriptional and translational level to regulate protein abundance but also happens at the post-
translational level where protein function as well as its abundance is regulated.   
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Figure 1.1 Cells interpret environmental cues to regulate biological processes 
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One mechanism of post-translational regulation is reversible protein phosphorylation.  
Kinases transfer the gamma-phosphate group of adenosine triphosphate (ATP) to serine, 
threonine and tyrosine residues on substrate proteins (Berg et al., 2007).  Substrate proteins can 
also be de-phosphorylated by phosphatases.  The sequence surrounding the serine, threonine and 
tyrosine residues (the target motif) enable kinases to specifically phosphorylate substrates.  
Substrate specificity is also provided by docking and interaction domains, scaffold proteins and 
subcellular localization.  A protein’s phosphorylation status can alter its conformation, its 
association with other proteins, determine its stability and ultimately regulate its function.  
Because of their ability to be dynamically and specifically regulated, living organisms utilize 
protein phosphorylation events as “cascades” to transmit information throughout the cell.   
In this work I will focus on three of the cells major signaling cascades: 1) extracellular 
signaling regulated kinase – mitogen activated protein kinase (ERK-MAPK) signaling cascade 
which is involved in cell proliferation, survival and migration, 2) p38-MAPK cascade which is 
involved in stress signaling to regulate cell survival, cell death and inflammatory response and 3) 
phosphatidylinositol-3 kinase-AKT-mechanistic target of rapamycin complex 1 kinase (PI3K-
AKT-mTORC1) pathway which is a master regulator of cell metabolism and growth.  These 
signaling pathways can be activated by extracellular matrix, growth factors and cytokines, which 
bind to cell surface receptors. Receptor activation leads to recruitment of signal intermediate 
proteins that activate a cascade of kinases, which lead to substrate phosphorylation and a 
biological output (Figure 1.2). 
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Figure 1.2 Cellular signaling can be initiated by cell surface receptors.  These receptors 
activate a cascade of kinases that transmits extracellular cues to downstream effector 
proteins to regulate biological processes.  Intermediate kinases are omitted for clarity.  
Yellow circles represent phosphorylation events.  See figures 1.4, 1.5 and 1.6 for details 
of ERK, p38 and AKT signaling cascades. 
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Even though signaling cascades were initially thought to be activated and regulated by 
distinct environmental cues to regulate separate biological processes, work over the past two 
decades has shown that cellular signaling cascades extensively communicate with each.  The 
Blenis laboratory is interested in answering two fundamental cell biological questions: How are 
different signaling pathways regulated in a coordinated fashion and what are the targets of 
signaling pathways that ultimately regulate biological processes such as cell proliferation, 
growth, migration, survival and cell death?  This dissertation describes two newly identified 
mechanisms of pathway crosstalk.  In Chapter 2, I will discuss how AKT regulates ERK-MAPK 
pathway by regulating EGFR degradation.  In Chapter 3, I will provide evidence for inhibition of 
p38-MAPK stress pathway by ERK-MAPK signaling and describe the mechanistic link between 
these two pathways.  In Chapter 4, I will give examples of newly identified substrates of ERK-
MAPK signaling pathway which help us understand how ERK signaling regulates biological 
processes such as migration, proliferation and survival. 
Epidermal Growth Factor Receptor Signaling 
Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase (RTK) that is 
essential for normal development (Sibilia et al., 2007).  EGFR belongs to the EGFR family of 
RTKs that include ErbB2, ErbB3 and ErbB4.  In the absence of their ligand, EGFR molecules 
form dimers and dissociate from each other at a constant rate.  Ligand binding stabilizes the 
EGFR dimers (Chung et al., 2010).  EGFR ligands include EGF, heparin binding EGF (HB-
EGF), betacellulin (BTC), transforming growth factor alpha (TGF-alpha), amphiregulin (AR), 
and epiregulin (EREG) (Yarden and Sliwkowski, 2001).  EGF, HB-EGF and TGF-alpha 
specifically bind EGFR with high affinity whereas BTC can also bind ErbB4 with high affinity 
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(Jones et al., 1999).  In addition to stabilizing homodimers of EGFR, ligand binding also causes 
receptor heterodimerization of EGFR with ErbB2, ErbB3 and ErbB4.  
Once stabilized EGFRs phosphorylate each other on multiple tyrosine residues. 
Phosphorylated residues on EGFR create docking sites for downstream signaling adaptors and 
scaffold proteins.  For example, upon activation, EGFR activates phospholipase-C gamma (PLC-
gamma) through PLC-gamma Src homology 2 (SH2) domain binding to EGFR phosphorylated 
at Tyr992 (pTyr992), which activates the downstream protein kinase C signaling (PKC) (Emlet 
et al., 1997) (Singer et al., 1997).  EGFR associates with growth factor receptor bound protein 2 
(GRB2) via EGFR pTyr1068 binding SH2 domains on Grb2.  EGFR-GRB2 association activates 
the small guanosine triphosphate hydrolyzing enzyme (GTPase) RAS, which initiates the ERK-
MAPK signaling cascade (Mendoza et al., 2011a).  GRB2 also recruits GRB2 associated binder 
1 (GAB1).  In turn, GAB1 brings the PI3K regulatory subunit p85 to the plasma membrane, 
which results in activation of the PI3K-AKT signaling cascade.  Through Tyrosine-X-X-
Methionine motifs, where X represents any amino acid, ErbB3 directly binds p85 in the context 
of EGFR-ErbB3 heterodimers and activates PI3K (Hellyer et al., 2001).  In addition to 
autophosphorylation of the receptors, active EGFR phosphorylates downstream substrates such 
as Vav2 and EGFR substrate 8 (EPS8) (Duan et al., 2011) (Fazioli et al., 1993). Vav2 and EPS8 
stimulate RAC1 GTPase activity (Duan et al., 2011; Scita et al., 1999).  On the other hand, 
Tyrosine 1045 phosphorylation recruits the Casitas B-lineage Lymphoma (Cbl) E3 ubiquitin 
ligase which conjugates single ubiquitin residues on multiple lysines on EGFR that target the 
receptor for trafficking to the lysosomal compartment where it gets degraded (Sorkin and Goh, 
2009).  PTP1B phosphatase dephosphorylates EGFR at the contact sites between the 
endoplasmic reticulum and the multi-vesicular bodies of the late endosomes, yet other 
8 
 
phosphatases may also act on phosphorylated EGFR in the cytoplasm (Eden et al., 2010) 
(Kleiman et al., 2011) (Figure 1.3).  Dephosphorylation and degradation terminate EGFR 
signaling. 
EGFR can activate the cell’s major signaling cascades that regulate proliferation, 
survival, metabolism, migration and cell death.  Therefore, it is not surprising that the loss of 
EGFR function in the developing organism can be lethal.  Knockout of the EGFR gene in mouse 
causes a plethora of developmental defects depending on the mouse strain. The most pronounced 
result of EGFR knockout is embryonic lethality and the survivors show epithelial defects in skin, 
hair and eyes as well as defects in heart, bone, brain and lung function (reviewed in (Sibilia et al., 
2007)).  Singly knocking out each of the EGFR ligands does not have as adverse effects possibly 
due to compensation from other ligands.  On the other hand, triple EGF, TGFalpha and AR 
knock-out causes abnormalities in skin, hair, eye and mammary gland functions, (reviewed in 
(Sibilia et al., 2007)), double BTC and HB-EGF null mice have shortened lifespan associated 
with heart failure (Jackson et al., 2003).  Despite the ligands ability to compensate for each other 
loss, over-expressing each ligand has shown non-overlapping functions.  For example, EGF 
over-expression causes infertility and growth retardation, BTC transgenic mice has a high rate of 
post natal mortality with reduced body size (Schneider et al., 2005) and TGF-alpha over-
expression causes epithelial hyperplasias of the mammary gland and liver (reviewed in (Sibilia et 
al., 2007)). 
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Figure 1.3 Simplified representation of EGFR regulating multiple signaling pathways. 
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In addition to regulation of proper development, EGFR signaling is also involved in 
pathogenesis of variety of human cancers.  EGFR over-expression is common in many forms of 
human cancers (Roberts and Der, 2007).  30% of the breast cancers over-express ErbB2, which 
is shown to up-regulate EGFR stability and function in 3-dimensional mamosphere models as 
well as in suspension (Grassian et al., 2011).  EGFR mutations are also a common driver event in 
tumorigenesis: 10% of non-small cell lung cancers and 20% of glioblastomas have hyperactive 
EGFR signaling due to EGFR mutations.  L834R mutation and deletion of exons 2 through 7 
(EGFR vIII) are among mutations that hyper-activate EGFR signaling (Riese et al., 2007).  
Pharmacological inhibition of the EGFR kinase causes cell death in many tumor cell lines that 
have hyperactive EGFR signaling, highlighting the addiction of these cells to EGFR signaling for 
cell survival.  Furthermore, a commonly observed mechanism of resistance to ATP competitive 
EGFR inhibitors is the EGFR T790M mutation.  This mutation causes structural change in the 
inhibitor-binding region of EGFR.  While the mutant EGFR can still bind ATP, it can no longer 
bind the inhibitor and therefore can resume downstream signaling even in the presence of the 
inhibitor.  
ERK-MAPK Signaling Cascade 
ERK is a serine-threonine kinase that phosphorylates serine or threonine residues of 
substrates within the target motif Pro-X-Ser/Thr-Pro where X is any amino acid.  Two isoforms 
of ERK, ERK1 and ERK2 share 84% amino acid sequence homology.  ERK is activated by G-
protein coupled receptors, integrins and growth factors (Roberts and Der, 2007).  In context of 
EGFR signaling, following ligand engagement, GRB2 binds directly to EGFR on pTyr1068 or 
through binding to Src homology domain containing transforming protein 1 (SHC1) which binds 
to EGFR on pTyr1173.  GRB2-EGFR interaction leads to membrane recruitment of guanine 
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nucleotide exchange factor (GEF) for the RAS GTPase: Son of Sevenless (SOS).  SOS-RAS 
interaction loads RAS with GTP and activates it.  GRB2 also binds GAB1.  Tyrosine 
phosphorylated GAB1 binds the RAS GTPase activating proteins (GAPs).  RAS-GAP proteins 
such as p120 and Neurofibromin 1 (NF1) enhance GTP hydrolysis by RAS, which inactivates 
RAS.  GAB1 is dephosphorylated by the SH2 domain containing protein tyrosine phosphatase 
(SHP2).  GAB1 dephosphorylated on its tyrosine residues has a lower affinity for p120 and 
therefore SHP2 mediated GAB1 dephosphorylation ensures continued RAS signaling.  Active 
RAS then recruits RAF isoforms, A-RAF, B-RAF and C-RAF to the plasma membrane for 
activation.  RAS binding induces RAF heterodimerization and protein phosphatase 2A (PP2A) 
mediated dephosphorylation of C-terminal serine residues, which bind the inhibitory 14-3-3 
proteins.  Through membrane recruitment dephosphorylation-phosphorylation cycles, hetero and 
homo-dimerizations, RAF proteins are released from their auto-inhibited state (McKay and 
Morrison, 2007).  RAF kinases are MAPK kinase kinases (MAPKKK) and have very narrow 
substrate specificity: they phosphorylate and activate the MAPK kinases MEK1 and MEK2 
(MAPKKK).  MEK is a dual specificity kinase that phosphorylates Tyr and Thr residues on 
ERK1-2 activation loops.  The only known substrate of MEK is ERK.  Having narrow substrate 
specificity kinases such as RAF and MEK allows for signal amplification and provides 
regulatory nodes for the signaling cascade, which will be described in detail in section 
“Temporal Regulation of Signaling Pathways”.  Active ERK phosphorylates a variety of 
substrates including transcription factors, cytoskeletal elements and structural proteins and 
effector kinases such as p90 ribosomal S6 kinase (RSK) and mitogen and stress activated kinase 
(MSK)  (Yoon and Seger, 2006) (Figure 1.4).   
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Figure 1.4 EGFR initiates the ERK-MAPK signaling by activating RAS small GTPase, 
which activates the RAF-MEK-ERK kinase cascade.  Active ERK phosphorylates 
effector proteins some of which are also kinases, such as p90 RSK. 
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RSK and MSK are members of the AGC family of kinases, which are named after protein 
kinase A (PKA) protein kinase G (PKG) protein kinase C (PKC).  This family also includes 
S6K1-2, AKT1-3, serum and glucocorticoid regulated kinase SGK1-3.  These kinases 
phosphorylate their substrates on basophilic amino acid sequences with the target motif Arg-X-
Arg-X-X-Ser/Thr (Pearce et al., 2010).  Arg residue 5 amino acids upstream (-5 position) of the 
phosphorylated serine and threonine can be substituted with Lys for RSK, MSK and S6K, 
however AKT has a stricter requirement for this -5 Arg at the target motif.  Among the other 
AGC kinase family members RSK and MSK are unique in that they have two catalytically active 
kinase domains.  The N-terminal kinase domain (NTKD) belongs to the AGC family whereas the 
C-terminal kinase domain (CTKD) belongs to the CamK family of kinases.  ERK 
phosphorylation of RSK Thr573 and MSK Thr581 promotes activation of their CTKD.  p38 
MAPK also phosphorylates and activates MSK in response to cellular stress.  On the other hand, 
RSK is activated by p38 only in dendritic cells via a p38 mediated MAPK activated protein 
kinase 2 and 3 (MK2-3) (Zaru et al., 2007).  Once activated the CTKD of MSK 
autophosphorylate Ser376, Ser381 in the linker region and the NTKD activation loop Ser212. 
CTKD of RSK S380 and create a docking site for phosphoinositide dependent kinase (PDK1).  
The activation loop of the NTKD of RSK is phosphorylated on Ser221 by PDK1 and is 
activated.  Once active, NTKDs of RSK and MSK phosphorylate substrate proteins. MSKs 
reside constitutively in the nucleus.  ERK and RSK phosphorylate cytoplasmic proteins and they 
translocate to the nucleus within minutes of activation (Chen et al., 1992) where together with 
MSKs target transcription factors involved in a variety of biological processes. 
ERK signaling is critical in development and deregulation has been implicated in a 
variety of human pathologies.  Deletion of the K-Ras in mice is embryonic lethal whereas H-Ras 
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or N-Ras deletion has no obvious phenotypes suggesting at the developmental stages there may 
be redundancy between different Ras isoforms (Johnson et al., 1997).  B-Raf and C-Raf deletion 
in mice is also embryonic lethal.  A-Raf deletion show neurological and intestinal disorders 
(Baccarini, 2005).  Similar to B-Raf, C-Raf and K-Ras deletion, Mek1 and Erk2 deletion in mice 
is also embryonic lethal whereas Mek2 and Erk1 null mice are viable with Erk1 null mice 
showing defects in the immune system and adipocyte differentiation (Aouadi et al., 2006; 
Belanger et al., 2003; Bissonauth et al., 2006).  RSK2 null mice have cognitive deficiencies as 
well as defects in white adipose tissue, whereas RSK1 and RSK3 null mice have no obvious 
phenotypes. In stark contrast to other members of the ERK signaling cascade, MSK1 and MSK2 
compound deletions and RSK1-RSK2-RSK3 compound deletions in mice have no obvious 
developmental defects, are viable and fertile suggesting there is a great deal of redundancy at this 
level of the MAPK signaling cascade (Cargnello and Roux, 2011).  Deregulation of this pathway 
is involved in both developmental disorders as well as human malignancies.  RASopathies are a 
class of human disorders in individuals with mutations in the RAS-MAPK signaling pathway.  
Mutations and deletions occur at the PTPN11 gene (encodes SHP2), KRAS, SOS1, RAF1, 
MAP2K1-2 (encode MEK1-2), RASA1 (encodes p120 RASGAP) and NF1 (encodes the RAS-
GAP NF1) (Tidyman and Rauen, 2009).  RAS mutations are among the most frequent events in 
human cancers.  RAF mutations are very common in human melanomas with the BRAF V600E 
being the most common.  MEK1 is also mutated as a resistance mechanism to RAF inhibition for 
reactivating ERK signaling (Emery et al., 2009).  ERK2 is also recently found to be amplified in 
cell culture models of drug resistance to EGFR inhibitors (Ercan et al., 2012). 
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p38 MAPK Signaling Cascade 
 p38 MAPK signaling cascade is the cell’s major stress response pathway.  p38 gets 
activated by cytokines, pathogens, environmental stress such as osmotic stress and reactive 
oxygen species (Cuadrado and Nebreda, 2010).  Just as in the ERK MAPK signaling cascade, 
p38 signaling cascade is initiated by MAPKKKs, including Apoptosis signal regulating kinase 
(ASK1), transforming growth factor beta (TGF-beta) activated kinase (TAK1) and MEKK3.  
Oxidative stress causes thioredoxin oxidation on its cysteine which frees ASK1 for 
autophosphorylation and activation (Matsukawa et al., 2004).  TGF-beta stimulation causes 
tumor necrosis factor (TNFalpha) receptor associated factor 6 (TRAF6) E3 ubiquitin ligase 
association with the TAK1 binding protein 1 (TAB1).  TRAF6 auto ubiquitination drives binding 
of TAB1: an event leading to activation of TAK1 through a mechanism that possibly involves 
oligomerization.  Osmotic stress causes osmosensing scaffold for MEKK3 (OSM) binding to 
RAC1, which brings MEKK3 to the plasma membrane (Uhlik et al., 2003).  MEKK3 is activated 
by oligomerization and autophosphorylation, which leads to phosphorylation of the downstream 
MAPKKs.  MKK3, MKK6 activate p38 isoforms by phosphorylating them on their activation 
loops whereas MKK4 and MKK7 are more established activators of the parallel MAPK 
pathway: the c-Jun N terminal kinase (JNK) cascade (Cargnello and Roux, 2011).  MEKK3 can 
also hetero-oligomerize with MKK5, which leads to activation of ERK5 (Sun et al., 2001).  Once 
activated p38 and ERK5 both phosphorylate proline directed serine and threonine residues on a 
variety of substrates that regulate the stress response.  Like ERK1 and ERK2, p38 
phosphorylates and activates MSK1 and MSK2.  RSK is activated by p38 and ERK5 only in 
dendritic cells and downstream of hyperactived MKK5, respectively, suggesting that RSKs 
activation is more specific to ERK1 and ERK2 than to p38 and ERK5 (Ranganathan et al., 2006; 
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Zaru et al., 2007).  On the other hand, MAPK activated protein kinase MK2 and MK3 are 
activated by p38 isoforms but not ERK1-2.  p38 also activates several transcription factors 
involved in apoptosis and immune response (Figure 1.5). 
p38 alpha knockout mice die in embryogenesis as do MKK3 and MKK6 double knockout 
mice suggesting a role for p38 activation during development (Cuadrado and Nebreda, 2010).  
However, deletion of other p38 isoforms is not lethal pointing out some redundancy during 
development.  Also, deletion of neither MKK3 nor MKK6 is embryonic lethal, however MKK3 
null mice have reduced immune response due to reduced cytokine production by the 
macrophages and dendritic cells (Lu et al., 1999).  Similarly, MEKK3 deletion also causes 
reduction in cytokine production, but in addition to reduced p38 signaling, inhibition of NFkB 
signaling, which can also be activated downstream of MEKK3, also contributes to this effect 
(Yang et al., 2001).  Both TAK1 and MEKK3 null mice are embryonic lethal with MEKK3 null 
mice showing inappropriate cardiovascular development (Tang et al., 2008; Yang et al., 2000).  
In contrast, ASK1 null mice are viable and fertile, however fibroblasts derived from these mice 
show reduced apoptosis in response to hyperosmotic shock and TNF alpha due to their inability 
to provide sustained p38 and JNK activation (Tobiume et al., 2001). 
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Figure 1.5 Various stress factors and cytokines activate MAPKKKs, which initiate a 
signaling cascade to MAPKKs to activate p38-MAPK.  Only MEKK3, TAK1 and ASK1 
are shown for simplicity.  Red circles represent ubiquitination events. Additional 
MAPKKKs have also been described (Cuadrado and Nebreda, 2010). 
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PI3K-AKT-mTORC1-S6K Signaling 
PI3K is a phosphoinositide kinase that phosphorylates the 3 position of the 
phosphatidylinositol.  There are three classes of PI3Ks that differ in their substrate specificity 
and function.  Class I PI3K is composed of two subunits, p85 (alpha and beta), p55, p150, p101 
or p87 are the regulatory subunits and p110 (alpha, beta, gamma and delta) is the catalytic 
subunit.  Class I PI3Ks phosphorylate the 3 position of phosphatidyl-inositol 4,5 bisphosphate 
(PI(4,5)P2) to generate PI(3,4,5)P3 whereas Class III phosphorylates only PI and Class II PI3K 
phosphorylate PI as well as PI(4)P (Engelman et al., 2006).   
In the context of insulin signaling, the activated insulin receptor gets cross-
phosphorylated on multiple tyrosine residues which recruit the insulin receptor substrate (IRS) 
proteins to the plasma membrane.  This is analogous to GRB2 recruitment by EGFR.  IRS1-2 
recruit the regulatory p85 subunit of the Class I PI3K to the plasma membrane. While providing 
structural stability to the p110, p85 also inhibits the basal PI3K activity.  RAS binding to the 
catalytic subunit p110 subunit further activates PI3K and this interaction is necessary for PI3K’s 
ability to induce oncogenic transformation.  A major effector of PI3K is AKT kinase (Franke et 
al., 1997). Interaction between the pleckstrin-homology (PH) domains on AKT and PI(3,4,5)P3 
recruit AKT to the plasma membrane where it is phosphorylated by PDK1 on Thr308.  AKT is 
fully activated by Ser473 phosphorylation which is carried out by mTORC2.  This complex is 
composed of rapamycin insensitive companion of mTOR (RICTOR), mammalian stress 
activated kinase interacting protein (mSIN1), mammalian lethal with Sec13 protein 8 (mLST8) 
and mTOR.   Signaling from the RTKs to AKT is antagonized by the phosphatase and tensin 
homolog (PTEN) phosphatase that dephosphorylates the 3 position of the PI(3,4,5)P3.   AKT2 
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can also be activated by PI(3,4)P2 that is generated by the PI5 phosphatase SHIP1-2.  PI(3,4)P2 is 
further dephosphorylated by INPP4 to PI(3)P (Gewinner et al., 2009).   
Once activated, AKT phosphorylates a variety of substrates involved in metabolism and 
protein synthesis leading to cell growth.  In 1994 our lab discovered the first clue that mTORC1 
signaling is downstream of PI3K signaling (Chung et al., 1994).  Two substrates of AKT are 
involved in connecting PI3K-AKT signaling to mTORC1 signaling.  mTORC1 is composed of 
the serine threonine kinase mTOR, mLST8, regulator-associated protein of mTOR (Raptor) and 
is bound by the inhibitory proline rich AKT substrate of 40kDa (PRAS40).   Phosphorylated 
PRAS40 is sequestrated by the 14-3-3 proteins and can no longer inhibit mTORC1 (Vander Haar 
et al., 2007).  AKT also phosphorylates tuberous sclerosis complex 2 (TSC2), when 
phosphorylated can no longer inhibit the small GTPase Ras homolog enriched in Brain (RHEB).  
RHEB in conjunction with RAG GTPases, which are activated downstream of the amino acid 
sensing pathway, activates mTORC1 complex (Sengupta et al., 2010).  In contrast, low energy 
levels in cells lead to liver kinase B1 (LKB1) mediated activation of AMP kinase, which 
phosphorylates and inhibits mTORC1(Shaw, 2009).  Two most established substrates of the 
mTORC1 complex, Eukaryotic elongation initiation factor 4E (EIF4E) binding protein (4E-BP1) 
and S6K, interact with Raptor via their Tor signaling (TOS) motif (Schalm and Blenis, 2002; 
Schalm et al., 2003).  4E-BP1 phosphorylation by mTORC1 dissociates 4E-BP1 from EIF4E 
which upregulates mRNA translation.  mTORC1 phosphorylation of S6K on Thr389 creates a 
docking site for PDK1 which in turn phosphorylate the activation loop of S6K.  Active S6K in 
turn phosphorylates a large number of substrates involved in mRNA translation, splicing and 
ribosome biogenesis (Figure 1.6). 
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Figure 1.6 Type I PI3Ks activate AKT downstream of RTKs.  Active AKT can directly 
regulate end point proteins and also activate mTORC1 by phosphorylating and inhibiting 
TSC2 and PRAS40 (not shown) both of which inhibit mTORC1 activity.   
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 Given the fact that PI3K signaling is a multifaceted regulator of growth and metabolism it 
is not surprising that it is one of the most frequently mutated kinase in human cancers (Steelman 
et al., 2011).  p110 alpha H1047R, E545K and E542K mutation hyper-activate the kinase activity 
leading to increased PIP3 production and AKT activation(Gymnopoulos et al., 2007).  The loss 
of the tumor suppressor PTEN either through mutational inactivation or deletion is a common 
event in human cancers and is the cause of Cowden’s disease which is characterized with benign 
tumors that can progress into malignancy (Krymskaya and Goncharova, 2009).  Similarly 
inactivation and loss of the mTORC1 negative regulators LKB1 and TSC2 lead to Peutz-Jeghens 
and tuberous sclerosis syndrome, respectively, both of which are characterized by small tumors 
throughout out the body (Krymskaya and Goncharova, 2009).  AKT1 is also mutated in variety 
of cancers.  AKT1 E17K mutation allows AKT1 PH domain to bind PI(4,5)P2 in addition to 
PI(3,4,5)P3 which facilitates AKT activation (Carpten et al., 2007).  Increased signaling 
downstream of AKT2 and AKT3 is achieved through their genomic amplification and the E17K 
mutations are much less common than observed for AKT1 (Steelman et al., 2011). 
 As increased PI3K signaling is associated with tumorigenesis, its reduction causes insulin 
resistance, which is part of the pathology of type 2 diabetes.  A major role of PI3K signaling is to 
increase hepatic glucose uptake in response to increasing levels of insulin in the plasma.  Once 
activated AKT phosphorylates the GAP for Rab8, AKT substrate of 160 (AS160) (Sano et al., 
2003).  Phosphorylation inhibits AS160 and therefore allows Rab8 function, which leads to 
localization of glucose transporter 4 (GLUT4) from the intracellular vesicles to cell surface.  
This allows for glucose uptake by the cells.  AKT also stimulates glycogen synthesis by 
phosphorylating and inhibiting glycogen synthase kinase 3 (GSK3). 
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Temporal Regulation of Signaling Pathways 
The importance of the ERK, AKT, p38 signaling cascades is underlined by the observation 
that loss of function of function of members of these pathways result in systemic defects during 
development.  On the other hand, hyper-activation of these pathways are involved in various 
human disorders and cancers.  Therefore, organisms tightly regulate the activity level of these 
pathways, through multiple mechanisms that involve pathway feedback, crosstalk as well as 
compensation (Mendoza et al., 2011a). 
1) Feedback 
The linear nature of the RAS-RAF-MEK-ERK cascade provides a platform for amplifying 
the mitogenic signals.  However, without the proper regulation of this platform, small changes in 
the input signal, such as EGF concentration, would lead to very large fluctuations in the output 
ERK activity.  The magnitude and duration of the ERK activity output are important in cellular 
decision making.  For example, nerve growth factor (NGF) stimulation of the PC12 cells results 
in a high and sustained ERK activity, which leads to differentiation.  On the other hand, EGF 
stimulation causes a transient ERK activity which leads to proliferation (Murphy and Blenis, 
2006).  The ability of NGF to stimulate stronger and sustained ERK activity has been attributed 
to the observation that NGF receptors are not degraded following stimulation, whereas EGF 
stimulation of EGFR causes receptor internalization and degradation in the lysosomes.  
Feedback termination of the EGFR signaling is mediated by EGF induced EGFR degradation 
(von Zastrow and Sorkin, 2007).  As mentioned above, activated and tyrosine phosphorylated 
EGFR recruits multiple adaptor and scaffold proteins to initiate signaling cascades.  Active 
EGFR also recruits components of the endocytic machinery which promote EGFR 
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internalization into the cells.  EGFR activity is required for the internalization processes since, 
EGFR catalytic inhibitors or expression of EGFR mutants that lack activity, preclude proper 
internalization.  Internalized EGFR localizes to the early endosomes marked by the early 
endosomal antigen 1 (EEA.1), which is a RAB5 effector protein.  From EEA.1 endosomes 
EGFR continues to signal and associate with GRB2 (Di Guglielmo et al., 1994).  Continued 
EGFR activity and monoubiquitination target it to the multi-vesicular bodies (MVBs).  
Monoubiquitins are recognized by endosomal sorting complex for transport (ESCRT) proteins 
and EGFR is sorted into the lumen of the MVBs where it is separated from the signaling 
proteins.  Once in the MVBs EGFR is destined to fuse with the lysosomes and the EGFR signal 
is terminated (Figure 1.7). 
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Figure 1.7 Regulation of EGFR signaling by endocytic trafficking.  EGFR can signal from 
the plasma membrane and the early endosomes.  Once sorted into the lumen of the MVB’s, 
EGFR is separated from signaling proteins and is destined for degradation, which causes 
signal termination. 
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ERK itself is a major regulator of the upstream components of the MAPK signaling pathway.  
ERK phosphorylates SOS, RAF and MEK1.  RSK activated by ERK phosphorylates GAB2 and 
SOS.  These data suggest that ERK feedbacks to all levels of the RAS-ERK cascade.   ERK 
phosphorylation of RAF reduces RAF activity by reducing RAF-RAS interaction (Ritt et al., 
2010).  When ERK phosphorylation sites on RAF are mutated to non-phosphorylatable Ala RAF 
can longer be inhibited by ERK.  In a population of cells, response to increasing doses of EGF 
results in a graded increase in ERK phosphorylation.  However, when ERK signaling to RAF is 
inhibited, ERK activation adapts a switch-like response to increasing stimulus (Sturm et al., 
2010).  This means that in response to small amounts of EGF the majority of cells do not activate 
ERK whereas a few cells activate ERK to the maximum extend.  As EGF concentration 
increases, the number of cells with maximum ERK activity increases.  This demonstrates how 
signaling feedback is required to prevent drastic fluctuation in the signaling output in response to 
small changes in the input.  ERK also feedback phosphorylates MEK1 which reduces the activity 
of MEK1-MEK2 heterodimers.  Mutation of this phosphorylation site on MEK1 increases ERK 
mediated fibroblast migration (Catalanotti et al., 2009).  Additionally, ERK activates RSK which 
phosphorylates of GAB2 on basophilic residues leading to reduced SHP2-GAB2 interaction 
(Zhang et al., 2013).  Because GAB1 is dephosphorylated on its tyrosine residues by SHP2, 
reduced GAB2 and SHP2 interaction may also increase GAB2 tyrosine phosphorylation.  Similar 
to GAB1, tyrosine phosphorylated GAB2 may also recruit RAS-GAPs and inactivate RAS 
signaling.  Consistently, mutation of GAB2 basophilic RSK phosphorylation sites increases ERK 
signaling and epithelial cell migration.  Despite all having physiological consequences at the 
cellular level perhaps the most significant mechanism of ERK mediated feedback is ERK and 
RSK phosphorylation of SOS1.  ERK and RSK mediated phosphorylation of SOS1 in the SOS1 
26 
 
proline rich region (PR) result in SOS1 dissociation from GRB2 and SOS1 binding to 14-3-3: 
events that prevent SOS1 activation of RAS (Corbalan-Garcia et al., 1996; Saha et al., 2012).  
Consistently, mutation of phosphorylation sites on SOS1 PR or deletion of this region results in 
hyper-activation of ERK.  In fact, deletion of SOS1 PR is a naturally occurring mutation, which 
causes hereditary gingival fibromatosis, which is one of the RASopathies (Hart et al., 2002).  
The discovery of S6K feedback to AKT signaling also carries medical implications.  Hyper-
activation of the mTORC1-S6K signaling axis is a common event in human cancers as judged by 
the high abundance of phosphorylated S6 protein in tumor samples from patient.  This makes 
mTORC1 signaling a favorable drug target.  However tumor samples collected from patients 
following treatment with Rapamycin display increased phosphorylation of AKT, suggesting S6K 
inhibition relieves the feedback inhibition of AKT (O'Reilly et al., 2006).  Accordingly, in cells 
were mTORC1 signaling is hyper-activated either through loss of PTEN, LKB1 or TSC2, insulin 
stimulation does not cause AKT activation to the maximum extend (Manning, 2004).  One of 
mechanistic basis for this observation is S6K phosphorylation of IRS1 on multiple serines, which 
reduces IRS1 stability and therefore disrupts signaling from the insulin or insulin like growth 
factor signaling to AKT.  This mechanism also operates in insulin resistant mice models of Type 
2 diabetes where insulin stimulation does not activate AKT, which correlates with a high level of 
IRS1 phosphorylation.  On the other hand S6K null mice are refractory to insulin resistance and 
high fat induced diabetes, which parallels the lower level of IRS1 serine phosphorylation.  This 
points out to a broken feedback loop where S6K can no longer inhibit AKT signaling and 
therefore AKT activation following insulin stimulation is still intact.  S6K also phosphorylates 
RICTOR and increases 14-3-3 binding to mTORC2 complex, which reduces mTORC2 
activation of AKT.  Interestingly, this mechanism seems to be specific to AKT activation as 
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RICTOR phosphorylation does not affect SGK or PKC activation by mTORC2 (Dibble et al., 
2009).  In addition to S6K mediated feedback to IRS1 and RICTOR, mTORC1 complex itself 
phosphorylates another signaling adaptor protein GRB10.  mTORC1 phosphorylation of GRB10 
induces its proteasomal degradation and therefore results in reduces receptor signaling to AKT 
(Yu et al., 2011). 
Feedback also occurs at the transcriptional level.  AKT phosphorylates the Fork head 
transcription factor FOXO3a.  Phosphorylates FOXO3a is retained in the cytoplasm by 14-3-3 
binding and can no longer initiate target transcription.  When AKT is inhibited, FOXO3a goes 
into the nucleus to initiate transcription of ErbB3 and IGF1R and enhances RTK signaling 
(Chandarlapaty et al., 2011).  ERK regulates transcription of two classes of signaling regulators.  
Members of the Sprouty family of proteins act both as a positive and negative regulator of EGFR 
signaling.  On one hand, tyrosine phosphorylated Sprouty acts a “decoy” for Cbl E3 ubiquitin 
ligase and prevents Cbl ubiquitination of EGFR (Rubin et al., 2003).  On the other hand, Sprouty 
proteins also interfere with Grb2 recruitment to the RTKs (McKay and Morrison, 2007).  The 
second class of signaling regulators is dual specificity phosphatases (DUSPs), which can 
dephosphorylate both Ser-Thr and Tyr residues.  DUSPs associate with ERK and other MAPKs 
such as JNK and p38.  DUSPs can regulate MAPKs by two distinct mechanisms.  First is the 
direct dephosphorylation of the MAPKs at their activation loop phosphorylation.  Nuclear 
DUSPs also anchor MAPKs in the nucleus where they can no longer be phosphorylated by the 
MAPKKs, which are exclusively cytoplasmic (Caunt et al., 2008).  p38 MAPK activity also 
increases DUSP transcription by enhancing ATF2 transcriptional activity (Breitwieser et al., 
2007).  MSK1-2 activation downstream of p38 also increases DUSP1 and interleukin 10 
transcription, the latter of which inhibits p38 through autocrine signaling however the 
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mechanism is unidentified (Ananieva et al., 2008; Mackenzie et al., 2013).  Judging by the 
extensive feedback regulation of the AKT and ERK signaling, one would hypothesize that the 
parallel p38 signaling is also regulated by multiple feedback loops (Figure 1.8).  One such 
example is the p38 phosphorylation of TAB1 (Cheung et al., 2003).  Mutation of the p38 
phosphorylation sites on TAB1 increases TAK1 activity towards MKK6 suggesting p38 reduces 
its own activity by inhibiting TAK1 activation (Singhirunnusorn et al., 2005).  MK2 and MK3 
activity are also required for TAB3 phosphorylation; however, whether this phosphorylation 
plays a role in feedback signaling is not known (Mendoza et al., 2008). 
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Figure 1.8 Feedback regulation of ERK, PI3K, p38 signaling pathways.  Downstream kinases 
can either directly phosphorylate and inhibit upstream signaling proteins or initiate transcription 
responses that inhibit these signaling cascades via various mechanisms. 
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2) Crosstalk 
Despite being viewed as linear signaling cascades even the earlier studies using pathway 
activation with distinct agonists or chemical or genetic inactivation of the certain members of 
these pathways suggested the amount of extensive “crosstalk” between these pathways.  For 
example, PI3K-AKT inhibition increases ERK signaling (Rommel et al., 1999; Zimmermann and 
Moelling, 1999).  Accordingly, AKT1 overexpression reduces ERK signaling (Irie et al., 2005).  
The underlying mechanism is thought to be through AKT phosphorylation of on Ser259 C-RAF 
which leads to 14-3-3 binding and sequestration of C-RAF (Rommel et al., 1997).  The same site 
is also known to be basally highly phosphorylated by another member of the AGC family of 
kinases PKA (Dhillon et al., 2002).  AKT can also phosphorylate and inhibit B-RAF on Ser428 
and Ser364 (Guan et al., 2000).  Mutation of Ser364 decreases 14-3-3 binding and increases B-
RAF heterodimerization with C-RAF, whereas the mechanism by which Ser428 phosphorylation 
inhibits B-RAF activity is not clear (Ritt et al., 2010).  However, AKT inhibition of B-RAF 
translates into reduced ERK activity only in the context of melanoma cells that carry the B-RAF 
activating mutation V600E (Cheung et al., 2008).  This observation suggests that additional 
mechanisms of AKT mediated ERK inhibition may exist in normal cells.  In addition to RAF 
isoforms, AKT also phosphorylates and inhibits ASK1 MAPKKK upstream of p38 and JNK to 
reduce chemotherapy induce apoptosis (Kim et al., 2001; Yuan et al., 2003).  AKT regulation of 
JNK may also be through regulation of GTP binding to RAC1 which is reduced upon RAC1 
phosphorylation by AKT on Ser71 (Kwon et al., 2000).  On the other hand, AKT activation is 
regulated by ERK, which phosphorylates GAB1 on multiple serine residues.  Inhibition of ERK 
increases GAB1-PI3K interaction (Yu et al., 2002).  Accordingly when these sites are mutated 
hyperactive MEK signaling can no longer inhibit AKT activation (Lehr et al., 2004).  p38 
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crosstalk to EGFR, ERK and mTORC1 also exists.  p38 phosphorylates and recruits RAB5 
effectors EEA1 and Rabenosyn-5 to the plasma membrane(Zwang and Yarden, 2006).  EGFR 
phosphorylation on its C-terminal domain along with activation of EEA.1 and Rabenosyn 
facilitates ligand independent EGFR internalization.  As opposed to the EGF induced EGFR 
internalization, p38 mediated EGFR internalization does not activate EGFR.  p38 activity also 
enhances ERK1-2 and MEK1-2 binding to protein phosphatase 2A (PP2A), which 
dephosphorylates and inactivates the MEK1-2 (Junttila et al., 2008).  Additionally, p38 activates 
p38beta activated protein kinase (PRAK), which phosphorylates and inhibits RHEB and 
therefore inhibits mTORC1 activity during energy stress (Zheng et al., 2011). 
Crosstalk between signaling pathways is not always inhibitory.  As mentioned previously 
RAS binding to p110 catalytic subunit allosterically activates PI3Ks.  ERK pathway also 
crosstalks to mTORC1 signaling.  Upon activation by expression of hyperactive RAS or 
stimulation with EGF and phorbol esters, ERK and RSK phosphorylate TSC2 and RAPTOR 
(Carriere et al., 2008; Carriere et al., 2011; Ma et al., 2005; Roux et al., 2004).   TSC2 
phosphorylation relieves the inhibition on mTORC1 and S6K, however the mechanism is not 
clear.  RAPTOR phosphorylation by ERK and RSK stimulate mTORC1 kinase activity in vitro 
(Carriere et al., 2008; Carriere et al., 2011).  RAPTOR is also phosphorylated by p38 in response 
to arsenide, but not to insulin suggesting that p38 can activate mTORC1 signaling in a context 
dependent manner (Wu et al., 2011).  p38 also up-regulates mTORC1 in control of cell size, 
however, whether RAPTOR phosphorylation contributes to this process is not known(Cully et 
al., 2010) (Figure 1.9). 
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Figure 1.9 Crosstalk between ERK, PI3K and p38 pathways.  These signaling 
interactions are detailed in the text and are often times cell type and context dependent. 
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 Crosstalk between PI3K-AKT, ERK and p38 pathways also takes place by means of 
these pathways acting on the same set of substrates.  For example, RSK and S6K both 
phosphorylate the estrogen receptor (ER) on Ser167 which enhances estrogen independent ER 
transactivation and ER driven transcription (Yamnik and Holz, 2010).  Ribosomal protein S6 
(rpS6) is phosphorylated on Ser235 and Ser236 by both RSK and S6K although Ser240 and 
Ser244 are exclusively phosphorylated by S6K (Roux et al., 2007).  Phosphorylation enhances 
rpS6 binding to the 5’ methyl guanosine cap of mRNAs and may enhance protein translation.  In 
regulation of mRNA translation, p38, S6K and RSK all regulate eukaryotic elongation factor 2 
kinase (eEF2K).  Phosphorylation of eEF2K on Ser359 by p38 is necessary for inhibiting its 
activity in vitro (Knebel et al., 2002).  Phosphorylation of eEF2K by RSK and S6K on Ser366 
also inhibits eEF2K which no longer can phosphorylate and inhibit eEF2.  Thus RSK and S6K 
enhance translation elongation by allowing eEF2 function (Wang et al., 2001). 
In regulation of cell proliferation AKT and RSK both phosphorylate the cyclin dependent 
kinase inhibitor p27 kip1.  Thr198 phosphorylation by RSK induces 14-3-3 binding and 
anchoring in of p27 kip1 where it inhibits RhoA and facilitates cell motility (Larrea et al., 2009).  
AKT phosphorylation of p27 kip1 on Ser157 also reduces p27 kip1 nuclear localization by 
disrupting its association with importin alpha (Shin et al., 2005b).  AKT, RSK and ERK also 
phosphorylate and inhibit a master regulator of cell proliferation and metabolism, glycogen 
synthase kinase 3 (GSK3).  ERK phosphorylation of GSK3alpha on Thr43 primes RSK to 
phosphorylate GSKalpha on Ser9.  In the context of insulin signaling, AKT is the major 
contributor to Ser9 phosphorylation.  However, in TSC2 null cells, where hyperactive S6K 
mediates feedback inhibition of AKT, S6K phosphorylates and inhibits GSK3 (Zhang et al., 
2006b).  Similarly the BCL2 associated agonist of cell death (BAD) protein is subject to 
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coordinated regulation by AKT, S6K and RSK.  AKT and S6K phosphorylate BAD on Ser136 
whereas RSK phosphorylates it on Ser112.  These phosphorylation events induce BAD binding 
to 14-3-3, which enables the pro-survival protein BCL2 to inhibit mitochondrial apoptosis (She 
et al., 2005).  Depending on the cell type and extracellular stimuli extensive functional 
redundancy between the AGC kinases RSK, AKT and S6K take place. Examples of crosstalk via 
AGC kinase redundancy are summarized in Table 1.1. 
Table 1.1 Examples of substrates that are phosphorylated by multiple AGC kinases (Mendoza et 
al., 2011a) 
Substrate Kinase Substrate Kinase Substrate Kinase 
ERalpha RSK, S6K BAD RSK, S6K,AKT TCP1 RSK, S6K 
rpS6 RSK,S6K YB-1 RSK,AKT EIF4B RSK, S6K,AKT 
eEF2K RSK, S6K GSK3 RSK, S6K,AKT RANBP3 RSK,AKT 
MAD RSK, S6K p27 KIP1 RSK, SGK,AKT AS160 RSK, SGK,AKT 
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CHAPTER 2 
AKT REGULATES EGFR DEGRADATION AND TRAFFICKING BY 
PHOSPHORYLATING AND ACTIVATING PIKFYVE 
 A revised version of this work has been submitted for publication.  Dr. Ashley Mackey 
and Dr. Lucia Rameh processed and analyzed the data with phosphoinositides metabolically 
labeled with tritium.  Human mammary epithelial cells immortalized with dominant negative 
p53, hTERT and over-expressing EGFR was generated by Dr. Michelle Mendoza. 
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Introduction 
EGFR is a major regulator of cell proliferation, growth, survival, metabolism and motility 
and is over-expressed or inappropriately activated in many cancers (Riese et al., 2007; Yarden 
and Sliwkowski, 2001).  EGFR carries out these functions by activating multiple signaling 
cascades, including PI3K-AKT, mTORC1-S6K, and ERK-RSK pathways.  PI3K, mTORC1 and 
ERK variably induce distinct cellular functions depending on the cell type, cell-cycle time, and 
pathway activation level and duration (Mendoza et al., 2011a).  In response to EGF stimulation, 
AKT, ERK and RSK all contribute to the activation of the mTORC1 – S6K pathway.  EGFR and 
these downstream signaling pathways are regulated via a network of feedback and cross-talk 
mechanisms (Mendoza et al., 2011a).   
Receptor endocytosis is a regulatory mechanism that promotes sustained and spatially-
regulated signaling by localizing receptors to signaling endosomes and by promoting receptor 
recycling to the cell surface (Schenck et al., 2008; von Zastrow and Sorkin, 2007; Zoncu et al., 
2009).  Alternatively, endocytosis can lead to signal attenuation by culminating in receptor 
degradation.  EGFR endocytosis is initiated by EGF binding to EGFR dimers at the plasma 
membrane (Chung et al., 2010).  Stabilization of EGFR dimers promotes EGFR activation and 
trans-phosphorylation.  Active EGFR is ubiquitinated by CBL E3 ligase and recruits the 
endocytic machinery.  Both clathrin-dependent (Goh et al., 2010) and clathrin-independent (Orth 
and McNiven, 2006; Sigismund et al., 2005) pathways contribute to EGFR endocytosis.  
Receptor internalization is followed by localization to EEA.1-positive endosomes, where cargos 
destined for recycling or degradation are separated (Lakadamyali et al., 2006; Leonard et al., 
2008).  EGFR molecules are recycled back to the plasma membrane from the early endosomes 
and the limiting membrane of multivesicular bodies (MVBs) in a RAB4- and RAB11-dependent 
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manner.  Recycled EGFRs engage in additional rounds of endocytosis and signaling (Scita and 
Di Fiore, 2010).  Alternatively, PTP1B can de-phosphorylate EGFR at the limiting membrane of 
MVBs (Eden et al., 2010; Haj et al., 2002).  Dephosphorylated EGFRs enter the MVBs lumen 
via the endosomal sorting complex for transport (ESCRT) complexes (Haglund et al., 2003; 
Sigismund et al., 2005).  These EGFRs are dissociated from signal-transducing molecules and 
signaling is terminated.  These EGFRs are destined for degradation in the lysosomes.  
Proteins involved in EGFR sorting and degradation such as EEA.1 and ESCRT proteins 
are recruited to the endocytic vesicles via their interaction with phosphoinositides.  For example, 
the endomembranes contain phosphatidyl-inositol-3-phosphate (PI3P), which is recognized by 
Fab1, YOTB, Vac1, EEA.1 (FYVE) domains found in these respective proteins.  Fab1 is a 
phosphoinositide kinase that phosphorylates PI3P to generate PI(3,5)P2.  The SAC3 
phosphoinositide phosphatase dephosphorylates PI(3,5)P2 at the 5 position to generate PI3P (Ho 
et al., 2011).  In yeast, deletion of Fab1 disrupts cargo sorting to the yeast vacuoles (Odorizzi et 
al., 1998).  The human homolog of Fab1 is called FYVE-containing Phosphoinositide 3-
Phosphate (PI3P) 5 Kinase, PIKfyve. The homolog forms a complex with associated regulator of 
PIKfyve (ArPIKfyve) and SAC3 at the endomembranes.   PIKfyve, facilitates and SAC3 inhibits 
the progression of early endosomes towards MVBs, suggesting PI(3,5)P2 promotes and PI3P 
inhibits vesicle progression (Sbrissa et al., 2007).  However, the regulation of the PIKfyve-
ArPIKfyve-SAC3 complex in mammalian cells is not well understood. 
Previous work has implicated Type I PI3Ks, which are activated by Insulin and EGF, in 
the modulation of vesicular trafficking.  Mutagenesis of the platelet derived growth factor 
receptor’s (PDGFR’s) binding site for the type I PI3K regulatory subunit p85 blocks PDGFR 
degradation (Joly et al., 1994).  PI3K catalytic subunit p110 recruitment to the plasma membrane 
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accelerates clathrin coat dynamics (Nakatsu et al., 2010).  Injection of p110alpha-blocking 
antibodies causes transferrin to accumulate within the cells, suggesting p110alpha facilitates 
transferrin recycling (Siddhanta et al., 1998).  Wortmannin, a fungal product that inhibits all 
PI3Ks, also suppresses transferrin recycling in vivo and reduces the rate of endosomal sorting in 
cell free systems (Barysch et al., 2009; Spiro et al., 1996).  Two recent developments prompted 
us to investigate whether PI3K signals through AKT to modulate trafficking: AKT inhibitors 
were found to increase protein levels of several RTKs and AKT knockdown reduces transferrin 
and EGF uptake (Chandarlapaty et al., 2011; Collinet et al., 2010).   
We investigated the role of AKT in EGFR trafficking and discovered a novel negative 
feedback loop in which EGF-mediated activation of AKT promotes EGFR progression through 
the early endosomes and EGFR degradation by activating the PIKfyve.  Multiple AKT inhibitors 
and AKT knockdown reduce EGFR progression through the early endosomes, the rate of EGFR 
degradation and PIKfyve activity in vitro and in cells.  Similarly, knocking down PIKfyve or its 
activator ArPIKfyve or treatment with the PIKfyve inhibitor reduces the rate of EGFR 
degradation.  The reduced rate of EGFR degradation produced by AKT inhibition is rescued by 
knockdown of the SAC3 phosphatase. Further, expressing the PIKfyve mutant that cannot be 
phosphorylated by AKT reduces EGFR degradation.  We propose a model in which AKT 
phosphorylates and activates PIKfyve to facilitate EGFR endosomal progression, thereby 
increasing EGFR degradation and dampening EGFR signaling. 
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Results 
AKT regulates EGFR degradation. 
EGF stimulation causes EGFR degradation via delivery to the lysosomes (Scita and Di 
Fiore, 2010).  In order to address the role of AKT in EGFR degradation, we chose to assess 
EGFR degradation in human mammary epithelial cells (HMECs), which express 4.5 x 105 EGFR 
molecules per cell (Spangler et al., 2010).  This concentration of EGFR is within the range of 
other cell lines commonly-used in endocytosis studies.  HeLa cells express 1.7 x 105 EGFRs per 
cell (Spangler et al., 2010).  MDA-MB-468 and A431 cells, which harbor amplified EGFR, 
express three  and six-fold more EGFR than HMECs, respectively (Filmus et al., 1985; Merlino 
et al., 1984; Ullrich et al., 1984).  Stable over-expression of EGFR in HMECs leads to 25-50% 
increase in the total EGFR level (Figure 2.1, Panel A), so the approximate number of EGFR 
molecules is 6 x 105.  We used the latter cells for our studies as they were more tractable to 
interrogation and exhibited a more intermediate EGFR expression level compared to the above 
mentioned commonly-used cell lines.  Stimulation of these HMECs with high concentrations of 
EGF (100ng/mL) induced a decrease in total cell lysate EGFR levels and this is abrogated by 
pre-treatment with the lysosomal inhibitor chloroquine (Figure 2.1 Panel B and C).  Similar to 
HeLa cells, 1ng/mL EGF does not cause EGFR degradation, suggesting a specific EGFR 
activation level is needed to either induce degradation or detect the degradation. 
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Figure 2.1 EGF stimulation causes EGFR degradation through lysosomes.  A. Human mammary 
epithelial cells were infected with EGFR encoding cDNA to moderately over-express EGFR.  B. 
HMECs were stimulated with 1 or 100ng/mL EGF.  Only 100ng/mL EGF stimulation causes 
EGFR degradation.  C. Lysosomal inhibitor chloroquine reduces EGFR degradation in a dose 
dependent manner. 
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We hypothesized that any perturbation of EGFR trafficking to the lysosomes would alter 
its degradation rate.  We treated cells with vehicle (DMSO), the dual PI3K-mTOR inhibitor 
PI103 (Knight et al., 2006) or the highly specific allosteric AKT inhibitor AKTVIII (Lindsley et 
al., 2005).  PI103 interferes with PI3K activity and thus reduces PI(3,4,5)P3, and AKT pS473 
and pT308 levels, leading to AKT inactivation.  AKTVIII stabilizes an AKT conformation in 
which the PH and kinase domains are locked together (Calleja et al., 2009).  This conformation 
is proposed to interfere with AKT membrane recruitment and PDK1 and mTORC2 access to 
AKT.  The inhibitor therefore reduces AKT pS473 and pT308 levels and AKT activation.  
Membrane recruitment of the PH domain containing protein GRP1 is unaffected by AKTVIII 
suggesting the drug specifically interferes with the AKT membrane recruitment (Green et al., 
2008).   
In HMECs pretreated with DMSO, EGF stimulation caused more than 80% of the cell’s 
EGFR to be degraded within 120 minutes (Figure 2.2, Panel A).  Pre-treatment with AKTVIII 
and PI103 for 30 minutes sufficiently blocked AKT S473 phosphorylation as expected.  
Furthermore, pretreatment of cells with these inhibitors reduced the rate of EGF-induced EGFR 
degradation.  A substantial amount of EGFR was detected even after 120 minutes of EGF 
stimulation.  This phenotype was specific to AKT inhibition, as blocking other signaling 
pathways downstream of EGFR, such as the mTORC1-S6K (Rapamycin) and ERK-RSK 
(U0126) pathways did not affect EGFR degradation (Figure 2.2, Panel A).   
Our observation that both PI103 and AKTVIII stabilize EGFR levels suggests PI3K is 
working through AKT to regulate EGFR degradation by modulating the trafficking of EGFR-
containing vesicles or by modulating EGFR protein synthesis.  To test this, we repeated the 
EGFR degradation assays in the presence of protein synthesis inhibitor cycloheximide (CHX).  
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Co-treatment of cells with CHX and PI103, AKTVIII, or a structurally distinct ATP-competitive 
AKT catalytic inhibitor A-443654 reduced EGFR degradation rates (Figure 2.2, Panel B).  The 
effect of A-443654 on EGFR degradation was not as potent as the AKTVIII inhibitor, potentially 
due to its decreased specificity (Okuzumi et al., 2009).  Consistent with our previous 
experiments, Rapamycin did not alter EGFR degradation.  These data indicate AKT controls 
EGFR degradation in a protein synthesis-independent manner.  We further validated AKT 
controls EGFR degradation by siRNA knockdown of AKT1.  Two different AKT1 siRNAs 
significantly increased the percent of EGFR left undegraded after 120 minutes (Figure 2.2, Panel 
C). AKTVIII inhibitor reduced EGFR degradation in T47D breast cancer cell line, which has 
very low EGFR expression (Charafe-Jauffret et al., 2006) suggesting AKT regulates EGFR 
degradation independent of the EGFR expression level (Figure 2.3).     
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Figure 2.2 AKT facilitates EGFR degradation. A. HMECs were starved for growth factors 
overnight and stimulated with EGF for the indicated amounts of time in the presence or absence 
of the indicated inhibitors.  B. Cells were stimulated as above in the presence of 10 μM CHX.  
Western blot images are representative of at least 3 independent experiments.  C. Cells were 
transfected with siRNAs targeting AKT1 or with Non-targeting AllStars control siRNA for 72 
hours and deprived of growth factors within the last 24 hours of transfection, treated with CHX 
for 30 minutes and stimulated with EGF. 
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Figure 2.3 AKT facilitates EGFR degradation in T47D cells.  Cells were deprived of serum and 
growth factors and stimulated with 10ng/mL EGF in the presence or absence of AKT inhibitor.   
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AKT inhibition prolongs EGF-EGFR occupancy in the early endosomes. 
 Stimulation of cells with PKC or G-protein coupled receptor agonists sequesters EGFR in 
a peri-nuclear region (Idkowiak-Baldys et al., 2009).  This blocks EGF access to EGFR and 
inhibits ligand-induced degradation.  To determine if AKT controls EGFR degradation by 
facilitating EGF access to EGFR, and the resulting EGFR internalization, we quantified the 
percent EEA.1 co-localization with Alexa-488 EGF 15 minutes after stimulation using immuno-
fluorescence.  AKTVIII treatment did not significantly alter EEA.1 co-localization with EGF 
(Figure 2.4, Panel A).  Similarly, AKTVIII did not alter EEA.1 co-localization with EGFR after 
30 minutes of EGF stimulation and did not cause EGFR accumulation in the peri-nuclear region 
(Figure 2.4, Panel B).  Together with the observation that AKT inhibition does not prevent 
EGFR phosphorylation (Figure 2.2, Panel C), these data suggest AKT does not promote EGFR 
degradation by controlling EGF-EGFR binding or their subsequent internalization. 
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Figure 2.4 AKT inhibitor does not alter EGF and EGFR internalization and 
localization to EEA.1 positive endosomes. HMECs were deprived of growth 
factors overnight and stimulated with A. 1ug/mL Alexa-488 labeled EGF 
(green) or B. with 100ng/mL EGF and labeled with the early endosomal marker 
EEA.1 (red) or EGFR (green).  Percent co-localization was measured and is not 
statistically significantly different between two different treatment groups, 
using bootstrap permutation test (Efron and Tibshirani, 1993). 
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In order to determine if AKT promotes EGFR degradation by controlling vesicle 
trafficking, we sought to identify the subcellular location of the EGFR that accumulates upon 
AKT inhibition at a later time point.  In the presence of AKTVIII, EGFR molecules that are not 
degraded are still phosphorylated (Figure 2.2 C).  Because PTP1B dephosphorylates EGFR 
before EGFR sorts into the lumen of the MVBs (Eden et al., 2010), we hypothesized the un-
degraded EGFR accumulates at the early endosomes or the limiting membrane of MVBs.  
Indeed, AKTVIII treatment increased EEA.1 co-localization with EGF and EGFR 60 minutes 
after EGF stimulation (Figure 2.5, Panels A and B).  To verify the increased EEA.1-EGF and 
EEA.1-EGFR co-localization indicates increased EGF and EGFR within EEA.1 positive 
endosomes, we quantified the integrated intensities of the EGF and EGFR signal in each 
endosome throughout confocal Z-stacks of DMSO and AKTVIII treated cells.  We plotted the 
cumulative probability distribution of endosomes against integrated EGF-EGFR intensity values.  
In AKTVIII cells, endosomal EGF and EGFR intensities were significantly higher for the same 
probability value, suggesting AKTVIII treatment increased the amount of EGF and EGFR in 
each endosome (Figure 2.5, Panels C and D).  To synchronize internalization, we stimulated cells 
with EGF at 4oC prior to moving the cells to 37oC for 60 min.  AKTVIII treatment increased 
EEA.1 co-localization with EGF and EGFR in this case as well (Figure 2.6).  Thus we conclude 
that upon AKT inhibition, un-degraded EGF and EGFR molecules accumulate in EEA.1-positive 
early endosomes.   
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Figure 2.5 AKT inhibition increases EGFR and EGF accumulation at the early endosomes. Cells 
were stimulated with A. 1μg/mL Alexa-488 Labeled EGF (green) or B. with 100ng/mL EGF for 
60 minutes and labeled with EGFR (green) and EEA.1 (red). EGF/EGFR co-localization with 
EEA.1 is depicted in yellow and pointed by arrows. Panels to the right are boxplots generated by 
MATLAB.  '+' sign are outliers; whiskers indicate maximum and minimum values. Lower end of 
the boxes, the middle line and the upper edge of the boxes are 25th, 50th and 75th quantiles, 
respectively. The median values indicated by redlines are statistically significantly different  
(p<0.05). C and D.  Cells were treated as in A and B.  Cumulative probability distribution of the 
integrated intensity of EGF and EGFR labeling in each endosome was plotted as detailed in 
Materials and Methods.  AKT reduces EGF and EGFR content of each endosome C (n>2300 
endosomes .p<10-7) D (n>900 endosomes p<10-9).  Kolmogorov Smirnov Test was used for 
calculating statistical significance of the non-normal distributions. 
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Figure 2.6 AKT inhibitor causes EGF and EGFR accumulation at the early endosomes also 
when endocytosis is synchronized at 4oC. Cells were stimulated with 1ug/mL Alexa-488 EGF at 
4 oC, washed once with ice cold PBS and translocated to 37 oC for 60 minutes with pre-warmed 
media with or without AKT inhibitor.  Co-localization of EEA1 (labeled with alexa-568) with 
EGF (labeled with alexa-488) and EGFR (labeled with alexa-647) was measured, box plots were 
generated as described in Figure 2.5. 
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AKT regulates EGFR recycling. 
Disruption of receptor recycling by introduction of a dominant-negative RAB4 decreases 
EGF degradation (McCaffrey et al., 2001).  This is thought to be due to the inhibition of 
continuous rounds of receptor endocytosis in which a subset of the EGFRs would have been 
degraded with each cycle.  We found that Rab11 knockdown reduces EGFR degradation (Figure 
2.7).  This suggests that interfering with vesicle recycling induces intracellular retention of 
vesicles, which prohibits additional rounds of EGF binding to EGFR and therefore additional 
rounds of the recycling and degradation decisions. 
We hypothesized AKT facilitates EGFR degradation by promoting receptor recycling and 
ensuring continuity of the internalization and degradation cycles driven by the EGF in the media.  
We used an established method to assay receptor recycling in which we measured median cell 
surface EGFR staining using flow cytometry at different time points: before EGF stimulation 
(Total), after 15 minutes of EGF stimulation (Pulse) and after washing the EGF-pulsed cells with 
acid to remove surface EGF and transferring the cells back to 37oC for 10-20 minutes to allow 
EGFR recycling back to the plasma membrane (Chase) (Sigismund et al., 2008).  The percent of 
recycled EGFR was calculated by the formula 100*((Chase-Pulse)/(Total-Pulse)).  We found 
AKT inhibition reduces the rate of EGF-induced EGFR recycling (Figure 2.8, Panels A and C).  
Because EGF induces both degradation and the recycling of EGFR, we also assayed EGFR 
recycling in response to TGFalpha, a distinct EGFR ligand that promotes EGFR recycling 
without significant degradation (Roepstorff et al., 2009).  TGFalpha induced more robust EGFR 
recycling than EGF and TGFalpha-induced EGFR recycling was also reduced by AKTVIII 
treatment (Figure 2.8, Panels B and C).   
51 
 
 
Figure 2.7 RAB11 knockdown reduces EGFR degradation.  Cells were transfected with two 
different siRNAs targeting RAB11.  Percent undegraded EGFR was calculated as described in 
Materials and Methods.  Results of two independent experiments are shown in the graph. 
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Figure 2.8 AKT facilitates EGF and TGFalpha induced EGFR recycling.  Cells were pre-treated 
with AKTVIII or DMSO for 20 minutes and stimulated with EGF A. or TGFα B. for 15 minutes.  
Percent recycling in C. was calculated as described in Materials and Methods.  Flow-cytometry 
histograms are representative of 3 independent experiments.  Solid purple histograms and T 
represent total EGFR surface labeling prior to any growth factor stimulation. Green histograms 
with 0' represent surface EGFR labeling after 15minutesof EGF (100ng/mL) stimulation. Pink 
(10') and Blue (20') histograms represent surface labeling of EGFR after allowing cells to recycle 
EGFR at 37oC for 10 and 20 minutes following a pulse of 15 minutes with EGF.  C.  Bar graph 
represents averages of 3 independent experiments with standard error of mean as error bars.  
AKT inhibitor causes statistically significant decrease in EGFR recycling by Bootstrap 
permutation test (p = 0.05).  FL-H1: green fluorescence intensity. 
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AKT regulates EGFR's lysosomal progression. 
AKT1 promotes the localization of CD89 targeted antigen to the lysosome associated 
membrane protein 1 (LAMP1)-containing vesicles (Lang and Lang, 2006; Lang et al., 2001).  
This suggests that AKT is also involved in lysosomal sorting.  To determine if the AKTVIII-
induced reduction in EGFR degradation could be due to a reduction in lysosomal sorting, we 
quantified the percent co-localization of LAMP2 with Alexa-488 EGF.  EGF stimulation for 30 
minutes caused a small amount of LAMP2 to co-localize with Alexa-488 EGF.  However, AKT 
inhibition did not significantly change the percent LAMP2 co-localization with EGF (Figure 
2.9). 
The low amount of LAMP2 and EGF co-localization suggests EGF might be getting 
degraded within the lysosomal compartment.  To reduce to loss of our EGF signal, we used 
chloroquine to inhibit lysosomal degradation (Figure 2.1, Panel C).  In the presence of 
chloroquine, AKTVIII significantly decreased the percent LAMP2 co-localization with EGF, 
suggesting AKT regulates sorting of EGF towards the lysosomes (Fig. 2.10, Panels A and B).  
Since EGF causes both EGFR recycling and lysosomal sorting, we also repeated the degradation 
assay with Betacellulin, an EGFR ligand that induces EGFR lysosomal sorting and degradation 
without detectable recycling (Roepstorff et al., 2009).  Consistent with a role for AKT in EGFR 
lysosomal trafficking, AKT inhibition reduced the rate of Betacellulin-induced EGFR 
degradation (Figure 2.10, Panel C). 
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Figure 2.9 AKT inhibition does not affect EGF localization to the lysosomes in 
the absence of chloroquine possibly due to EGF degradation by lysosomal 
proteases.  Cells were stimulated with Alexa-488 EGF (green) and labeled with 
the lysosomal marker LAMP2 (red).  The average of more than 30 fields of image 
is given with standard deviations.  Average co-localization of LAMP2 with EGF 
is not statistically significantly different between two treatment groups. 
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Figure 2.10 AKT regulates EGF localization to lysosomes. A.  Cells pre-treated with 100mM 
chloroquine for three hours and stimulated with Alexa-488 EGF (green) and labeled for LAMP2 
(red).  Yellow represents co-localization. B.  Quantification and boxplot presentation of LAMP2 
co-localization with EGF.  AKT inhibitor statistically significantly reduces LAMP2 co-
localization with EGF (p<0.05)  C. Cells were starved for growth factors overnight and pre-
treated with DMSO or AKTVIII for 45 minutes and CHX for the last 30 minutes of inhibitor 
treatment and stimulated with Betacellulin for the indicated time points. 
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Because the observed reductions in total cellular EGFR levels could be influenced by 
alterations in EGFR ubiquitination (Vivanco et al., 2010), we determined if AKT regulated 
EGFR ubiquitination.  AKTVIII treatment did not alter EGFR ubiquitination (Figure 2.11), 
consistent with our conclusion that AKT promotes EGFR degradation by regulating EGFR 
progression from early endosomes towards recycling endosomes and lysosomes. 
AKT regulates EGFR degradation by phosphorylating and activating PIKfyve. 
We next investigated the mechanism by which AKT controls endocytic vesicle 
progression.  Endosomal identity and ability to progress within the vesicular trafficking system is 
dictated by the vesicle's phosphoinositide composition (Poccia and Larijani, 2009; Sbrissa et al., 
2007).  For example, increases in PI(3,5)P2  levels promote the progression of early endosomes 
into MVBs.  Insulin stimulation, which activates AKT, increases PI(3,5)P2 phosphoinositide 
levels by inhibiting SAC3 phosphatase activity (Ikonomov et al., 2009b).  Thus, we tested if 
AKT functioned upstream of or in a pathway parallel with SAC3 to facilitate early endosome 
progression and EGFR degradation.  SAC3 knockdown rescued the reduction in EGFR 
degradation induced by AKT inhibition (Figure 2.12, Panel A).  When de-convolved, 3 out of 4 
siRNAs in the SAC3 siRNA pool reproduced this phenotype, confirming acceleration of EGFR 
degradation is an on-target effect of the SAC3 siRNAs (Figure 2.12, Panel B).  These data 
indicate SAC3 functions downstream of or in a pathway parallel with AKT to regulate EGFR 
degradation. 
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Figure 2.11 AKT does not regulate EGFR ubiquitination.  Cells were deprived of growth 
factors and stimulated with EGF for 5 or 10 minutes.  EGFR was immuno-precipitated 
and labeled with ubiquitin or EGFR antibodies. WCL: whole cell lysate, IP: immuno-
precipitation. 
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Figure 2. 12 A. SAC3 knockdown rescues AKTVIII mediated reduction in EGFR degradation.  
Bottom panel: cDNA levels following SAC3 knock down, graph to the left shows quantification 
for EGFR degradation rates. B. siRNA pool de-convoluted: except for SAC3-2 all other siRNAs     
rescue the reduced EGFR degradation caused by AKTVIII treatment. 
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Because Insulin stimulation has been shown to inhibit SAC3, we tested if AKT directly 
regulates SAC3 phosphatase activity (Ikonomov et al., 2009b).  We immuno-precipitated the 
SAC3-ArPIKfyve-PIKfyve complex from human embryonic kidney 293T (HEK 293T) cells 
pretreated with or without AKT inhibitor.  Pretreatment of cells with AKT inhibitor did not 
change SAC3 phosphatase activity (Figure 2.13).  Scansite and PhosphoSite programs do not 
find a consensus AKT phosphorylation motif on SAC3, collectively suggesting that AKT does 
not directly regulate SAC3 (Hornbeck et al., 2011; Obenauer et al., 2003).   
However, the SAC3-associated PIKfyve was previously found to be phosphorylated by 
AKT in vitro and in vivo (Berwick et al., 2004; Hill et al., 2010).  To test if PIKfyve regulates 
EGFR degradation similar to AKT, we perturbed PIKfyve function.  Knockdown of PIKfyve or 
its activator ArPIKfyve, or PIKfyve inhibition using the PIKfyve inhibitor YM201636 (Jefferies 
et al., 2008) reduced the rate of EGFR degradation (Figure 2.14, Panels A, B and C).   Together 
these results suggest that similar to AKT activity, PIKfyve activity also facilitates EGFR 
degradation. 
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Figure 2.13 AKT does not regulate SAC3 phosphoinositide phosphatase activity.  
SAC3-ArPIKfyve-PIKfyve complex was immunoprecipitated from HEK 293T cells 
treated with or without AKT inhibitor and phosphoinositide phosphatase activity of the 
complex was measured as described in Materials and Methods. 
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Figure  2.14 PIKfyve regulates EGFR degradation.  Cells were transfected with siRNAs 
targeting PIKfyve, ArPIKfyve or treated with PIKfyve inhibitor YM201636 or DMSO.  EGFR 
degradation was performed and undegraded EGFR was compared to control cells. * indicates 
statistical significance p < 0.05, with Bootstrap permutation test.  Error bars are standard error of 
the mean. 
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Incubation of AKT with PIKfyve in vitro increases PIKfyve activity towards PI3P to 
generate PI(3,5)P2, suggesting AKT activates PIKfyve (Berwick et al., 2004).  However, the 
effect of mutating the AKT consensus sites on PIKfyve activity is not known.  We first 
confirmed AKT regulates PIKfyve phosphorylation using immuno-precipitated FLAG-PIKfyve 
transiently expressed in HEK 293T cells.  Western blotting with phospho-AKT substrate (pAS) 
antibody, which recognizes the consensus AKT phosphorylation motifs (Arg-X-Arg-X-X-
Ser/Thr) only when the Ser or Thr residues are phosphorylated, detected a band co-migrating 
with the FLAG PIKfyve protein (Figure 2.15).  Both AKTVIII treatment and mutation of one of 
the AKT consensus phosphorylation site Ser318 to an alanine substantially reduce the pAS 
signal (Figure 2.15), confirming AKT phosphorylates PIKfyve on S318. 
When activated, PIKfyve phosphorylates PI(3)P to generate PI(3,5)P2, which is then 
dephosphorylated by the myotubularin family of phosphatases to generate PI(5)P.  PIKfyve 
depletion in fibroblasts or treatment with PIKfyve inhibitor results in approximately 85% 
decrease in PI(5)P levels, suggesting most cellular PI(5)P is generated by the sequential action of 
PIKfyve and myotubularins (Zolov et al., 2012).  In order to test whether AKT inhibition and 
reduced PIKfyve phosphorylation correlates with PIKfyve activity in cells, we measured 3H 
labeled phosphoinositide species isolated from HMECs using phosphoinositide extraction, 
deacetylation and high performance liquid chromatography as previously described (Sarkes and 
Rameh, 2010).  Due to its very low abundance in cells we could not detect PI(3,5)P2 (Sarkes and 
Rameh, 2010).  However, the PI(5)P levels were reduced upon PIKfyve inhibitor treatment 
confirming that PI(5)P levels in cells reflects PIKfyve activity (Figure 2.16).  AKT inhibitor 
treatment also variably reduced PI(5)P levels suggesting that PIKfyve activity may be regulated 
by AKT in vivo, yet further experiments are required to strengthen this hypothesis.  
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Figure 2.15 AKT activity is required for PIKfyve Ser318 phosphorylation.  PIKfyve was 
immuno-precipitated from HEK293T cells treated with or without AKT inhibitor and 
phosphorylation of PIKfyve was assessed by western blotting with the phospho-AKT 
substrate antibody (pAS).  Wildtype (WT) but not S318A point mutant is phosphorylated. 
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Figure 2.16 AKT and PIKfyve activity regulate PI(5)P levels in cells.  HMECs were 
metabolically labeled with myo-3H-inositols and phosphoinositides were extracted and 
measured.  Depicted is the PI5P abundance from cells treated with different inhibitors as 
percentage of PI4P abundance.  Similar results were obtained when PI5P abundance was 
compared to total PI abundance. Exp #1 is the first and Exp #2 is the second experiment.  
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To determine if AKT directly regulates PIKfyve, we tested the effect of AKT inhibition 
or mutation of the AKT phosphorylation sites on PIKfyve's in vitro kinase activity by immuno-
precipitating the PIKfyve-ArPIKfyve-SAC3 complex from cells stimulated with or without EGF 
and pre-treated with DMSO or AKTVIII.  The immuno-precipitated complex was incubated in 
vitro with PI3P and 32P-ATP to generate radiolabeled PI(3,5)P2.  Resulting radiolabeled 
phosphoinositides were extracted and separated by thin layer chromatography (TLC) and the 
radioactive PI(3,5)P2 was quantified by Phospho-Imager.  EGF stimulation increased PIKfyve 
kinase activity which was reduced by pre-treatment of cells with AKT inhibitor, suggesting AKT 
is required for PIKfyve activation upon EGF stimulation (Figure 2.17, Panel A).  Mutation of the 
Ser318 AKT phosphorylation site on PIKfyve to un-phosphorylatable alanine increased basal 
PIKfyve activity, but blocked EGF-induced PIKfyve activity (Figure 2.17, Panel B).  To test if 
the S318A mutant's increased basal activity was due to phosphorylation at the second AKT 
target site, Ser105, we mutated both sites to Alanine.  Mutation of both serines mimicked the 
effect of AKT inhibitor on PIKfyve activity (Figure 2.17, Panel C).  Taken together with the 
observations that AKT regulates PIKfyve phosphorylation and PIKfyve activity in cells, these 
data suggest AKT directly activates PIKfyve phosphoinositide activity. 
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Figure 2.17 AKT phosphorylation activates PIKfyve.  PIKfyve complex was isolated from 
HEK293T cells. 1/11th of the complex was used for western blotting to ensure equal immuno-
precipitation of the complex from each condition. The rest of the PIKfyve complex was used in 
an in vitro phosphoinositide kinase assay using PI3P vesicles as a substrate.  Resulting 
radioactively 32P labeled PI(3,5)P2 was seperated by thin layer chromatography and visualized by 
Phospho-Imager.  
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To determine the role of AKT phosphorylation of PIKfyve in EGFR degradation, we 
transiently-expressed wild-type (WT) PIKfyve or the S318A mutant PIKfyve together with 
SAC3 and ArPIKfyve in HEK 293T cells.  Expression of the S318A mutant caused a small but 
statistically significant reduction in EGFR degradation and increase in phospho-EGFR levels 
compared to WT PIKfyve (Figure 2.18).  Taken together these data suggest that AKT enhances 
EGF induced EGFR degradation by phosphorylating and activating PIKfyve.   
In addition to EGFR degradation, PDGFRβ degradation was also reduced by PIKfyve 
and AKT inhibitors suggesting that this pathway is likely to be functional in degradation of other 
RTKs (Figure 2.19). 
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Figure 2.18 Mutation of AKT phosphorylation site reduces EGFR degradation and 
increases phosphorylated EGFR.  HEK293T cells were transfected with WT or S318A 
mutant PIKfyve and ArPIKfyve and SAC3.  EGFR degradation was measured.  pEGFR 
is EGFR phosphorylated at Tyr1068.  * indicates statistical significance (p < 0.05) 
measured by bootstrap permutation test.  Western blot is representative of at least three 
experiments. 
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Figure 2.19 PIKfyve and AKT regulate PDGFR degradation.  HMECs were deprived of growth 
factors overnight and stimulated with PDGF-BB in the presence of the indicated inhibitors and 
PDGFR degradation was quantified.  Statistical significance was calculated * indicates statistical 
significance (p < 0.05).   
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AKT reduces ERK signaling by facilitating EGFR degradation. 
Because receptor endocytosis can regulate receptor signaling to downstream pathways, 
we hypothesized AKT regulated EGFR degradation constitutes a negative feedback loop that 
reduces EGFR signaling.  In this model, EGF stimulation activates EGFR, which activates AKT.  
AKT directly phosphorylates and activates PIKfyve, which then promotes progression of early 
endosomes containing EGFR into the degradation path.  This activated endocytic trafficking 
promotes EGFR degradation and would therefore result in reduced EGFR signaling to the RAS-
RAF-MEK-ERK-RSK.  We tested the functionality of this negative feedback loop in the 
MCF10A normal breast epithelial cell line, which is a well-established system to study the cross-
talk between AKT and ERK pathways (Irie et al., 2005).  In these cells, AKT inhibition reduced 
EGFR degradation and led to more sustained ERK signaling as judged by EGFR, phospho-ERK 
and phospho-RSK levels following EGF stimulation (Figure 2.20). 
  To confirm that AKT feeds back to EGFR rather than a parallel pathway that regulates 
ERK signaling, we tested whether increased ERK activity by AKT inhibition could be 
suppressed by EGFR inhibition.  We treated MCF10As with or without AKTVIII in combination 
with an EGFR inhibitor.  Consistent with the hypothesis that AKT regulates EGFR signaling to 
modulate ERK activity, EGFR inhibition reduced phospho-ERK levels even in the presence of 
AKT inhibitor VIII (Figure 2.21). 
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Figure 2.20 AKT facilitates EGFR degradation and reduces ERK signaling.  MCF10A 
cells were stimulated with EGF and EGFR degradation was quantified.  The decrease in 
EGFR degradation upon AKT inhibitor treatment correlates with sustained ERK and 
RSK phosphorylation. 
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Figure 2.21 ERK activation upon AKT inhibition depends on EGFR activity.  MCF10A 
cells were stimulated with EGF for 120 minutes and ERK phosphorylation was 
determined in the presence of the indicated inhibitors.  Gefitinib: EGFR inhibitor, G+A; 
Gefitinib and AKT inhibitor co-treatment. 
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Conclusions and Future Directions 
A Role for AKT in EGFR trafficking and turnover 
While PI3Ks and their lipid products have been implicated in endocytic trafficking, and 
trafficking of EGFR, which PI(3,4,5)P3–binding proteins mediate these effects has not been 
explored.  Here we show AKT regulates EGFR trafficking and determined the molecular 
mechanism behind this regulation (Figure 2.22).   
Our results uncover a novel feedback loop by which AKT regulates EGFR degradation.  
Inhibition of AKT reduces recycling and lysosomal sorting of EGFR, which correlates with an 
increase in EGFR early endosomal localization and decreased PIKfyve activity in vitro and in 
vivo.  Reduced AKT activity enhances ERK and RSK activation in an EGFR dependent manner.  
Thus, we propose a model in which AKT negatively feeds back to EGFR to inhibit EGFR 
signaling to its downstream pathways:  1) AKT phosphorylates and activates PIKfyve which 
generates PI(3,5)P2,  2) PI(3,5)P2 facilitates the progression of EGFR-containing early 
endosomes to MVBs and late endosomes, and 3) EGFR degradation increases and EGFR 
signaling to ERK decreases.  Because AKT is upstream of the general endocytic regulator 
PIKfyve, this model suggests AKT may regulate the degradation of other RTKs as well.  
Supporting this hypothesis we found AKT and PIKfyve also regulate PDGFRβ degradation.   
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Figure 2.22 Model for AKT mediated EGFR degradation. When AKT is active it phosphorylates 
and activates PIKfyve to enhance EGFR degradation.  When AKT is inhibited EGFR 
degradation is slowed down due to impaired activation of the PIKfyve complex. 
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Role for PIKfyve-ArPIKfyve-SAC3 in receptor tyrosine kinase degradation 
Previous studies on PIKfyve’s role in RTK degradation have been inconclusive.  PIKfyve 
and its product PI(3,5)P2 regulate retro-grade trafficking and vesicle budding, degradation of 
Notch and voltage gated calcium channel Cav1.2 (Ho et al., 2011).  Yet, while two structurally-
similar PIKfyve inhibitors reduce EGFR degradation and sorting to the lysosomes (de Lartigue et 
al., 2009; Jefferies et al., 2008), PIKfyve knockdown does not interfere with EGFR degradation 
in HeLa cells (Rutherford et al., 2006).  The different results obtained by different groups could 
be due to cell type specificity, non-specific effects of the inhibitors or inefficient RNAi 
knockdown.  Alternatively, manipulating expression of one component of PIKfyve-SAC3-
ArPIKfyve complex can change the stoichiometry of proteins within this complex and therefore 
can produce a phenotype different than the one observed by directly inhibiting the kinase activity 
of an intact complex.  For example, in contrast to the aberrant vacuolation observed in PIKfyve 
inhibition(de Lartigue et al., 2009; Jefferies et al., 2008), expressing a PIKfyve mutant (K2000E) 
with lowered phosphoinositide kinase activity does not cause a morphological defect unless it is 
expressed together with SAC3 and ArPIKfyve (Ikonomov et al., 2009a).  Similarly, knockdown 
of SAC3 increases PI(3,5)P2 (Ikonomov et al., 2009b; Sbrissa et al., 2007), however SAC3 
knockout decreases PI(3,5)P2 levels possibly due to disruption of the complex integrity and/or 
function (Zolov et al., 2012). 
Given that relative abundances of these proteins in cells determine the phenotypes 
observed, we utilized knockdown and exogenous expression together with pharmacological 
inhibition to determine if PIKfyve-ArPIKfyve-SAC3 complex regulates EGFR degradation.  We 
show SAC3 knockdown, which increases PI(3,5)P2 levels, rescues the reduction in EGFR 
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degradation produced by AKT inhibitor treatment.  Conversely, knockdown of ArPIKfyve or 
PIKfyve, both of which are required for PI(3,5)P2 generation, reduces EGFR degradation. 
Inhibiting PIKfyve kinase activity and expressing the AKT phospho-site PIKfyve mutants which 
are deficient in phosphorylating PI3P to generate PI(3,5)P2 reduce EGFR degradation.  Thus, we 
conclude PIKfyve regulates EGFR degradation by generating PI(3,5)P2.  The observations that 
PIKfyve inhibitors reduce c-MET (de Lartigue et al., 2009) and PDGFRβ degradation suggest 
that PI(3,5)P2 and enzymes involved in its metabolism are general regulators of RTK 
degradation.  It is likely that PI(3,5)P2 controls RTK degradation either by recruitment of effector 
proteins that are involved in endosomal sorting and/or by directly activating ion channels thereby 
increasing endosome/lysosome fusion events(Dong et al., 2010; Wang et al., 2012) 
Regulation of PIKfyve 
Despite reducing PIKfyve activity in cells and in vitro, AKT inhibitor did not fully inhibit 
PIKfyve activation in response EGF.  PIKfyve can get activated in response to anaplastic 
lymphoma kinase (ALK) tyrosine kinase.  PIKfyve contain many phosphorylated tyrosines, thus 
whether EGFR can directly activate PIKfyve remains to be determined.  It is also possible that 
EGFR activates another tyrosine kinase, such as Src, to activate PIKfyve.  Because both Ser318 
and Ser105 follow the AMPK consensus phosphorylation site, it will be interesting to determine 
whether AMPK can phosphorylate and activate PIKfyve.  Another question that remains is how 
AKT phosphorylation regulates PIKfyve activity.  One possibility is AKT phosphorylation 
regulates PIKfyve association with 14-3-3 proteins as sequence surrounding Ser318 is a 
moderately strong 14-3-3 binding motif.  PIKfyve functions as an oligomeric complex.  We did 
not observe any changes in PIKfyve binding to SAC3 or ArPIKfyve in response to EGF, AKT 
inhibitor or mutation of the AKT phosphorylation sites suggesting that the stoichiometry of the 
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trimeric complex is not regulated by AKT.  However, whether or not multimeric complex 
assembly can be regulated by AKT needs to be tested.  Another possibility is that AKT regulates 
PI3P binding by PIKfyve because both of the AKT phosphorylation sites span the FYVE domain 
of PIKfyve.   
AKT substrates involved in receptor recycling 
We also found in HMECs, AKT facilitates EGFR recycling.  AKT regulates β1 integrin 
recycling by phosphorylating ACAP-1 and increasing ACAP-1 association with β1 integrin (Li 
et al., 2005).  EGFR and β1 integrin recycling are coupled by RAB coupling proteins (Caswell et 
al., 2008).  However, ACAP-1 over expression does not inhibit EGFR's lysosomal trafficking (Li 
et al., 2007), suggesting AKT targets involved in receptor recycling are distinct from those 
involved in degradation.  AKT phosphorylates and inhibits AS160 (Kane et al., 2002; Sano et al., 
2003), a RAB8 effector that restricts GLUT4 localization to specialized intracellular vesicles. 
Accordingly, AKT is necessary and sufficient for Glucose Transporter 4 (GLUT4) localization to 
the cell surface upon insulin stimulation (Ng et al., 2008).  
We found that AKT regulates both EGF and TGFalpha-induced EGFR recycling.  
Current models of EGFR recycling suggest EGF-EGFR complexes are stable at early endosomal 
pH and their dissociation and subsequent recycling occurs primarily in a slow, RAB11-
dependent manner, whereas TGFalpha-EGFR complexes are unstable at the early endosomal pH 
and their dissociation and subsequent recycling occurs in a fast, RAB4-dependent manner 
(Sorkin and Goh, 2009).  AKT physically associates with RAB11 in 293T cells when stimulated 
with lysophosphatidic acid (Garcia-Regalado et al., 2008), suggesting AKT may regulate RAB11 
or its associated proteins.  Thus, in addition to AKT regulating EGFR recycling by facilitating 
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EGFR exit from EEA.1 positive early endosomes, AKT may directly regulate RAB11-positive 
recycling endosomes.  However, the mechanism by which AKT regulates RAB4 mediated 
recycling is still not clear.   
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CHAPTER 3 
RSK REDUCES P38-MAPK ACTIVATION AND SIGNALING BY 
PHOSPHORYLATING AND INHIBITING MEKK3 
 Work presented in this chapter is not yet published.  Analysis of the mass spectrometry 
experiments was carried out by Dr. Bo Zhai and Dr. Steve Gygi.  The analysis of MEKK3 
mutations on cell death and proliferation will be carried out by Dr. Michal Nageuic. 
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Introduction 
 ERK is a major regulator of cell proliferation, survival and migration.  ERK carries out 
its functions in part by activating the p90 RSK isoforms and MSKs (Cargnello and Roux, 2011).  
In earlier unbiased studies to identify RSK substrates MEK1-2 inhibitors were utilized (Moritz et 
al., 2010).  Unfortunately MEK1-2 inhibitors can also block ERK5 activation.  Additionally, 
inhibiting ERK1-2 reduces growth factor mediated activation of the RSK related MSK1-2 
(Cargnello and Roux, 2011).  Given both RSK and MSKs phosphorylate basophilic sites on 
substrates, discriminating between de novo RSK substrates and MSK substrates has been 
challenging.  For example, even though cyclic AMP response element (CREB) phosphorylation 
in response to mitogens was initially thought to be driven by RSK, studies in MSK1-2 double 
knock-out mouse embryonic fibroblast demonstrated that MSKs are mainly responsible for this 
phosphorylation (Arthur and Cohen, 2000).  To find de novo targets of RSK signaling, we 
utilized the RSK specific inhibitor BI-D8170 (Sapkota et al., 2007).  Using an unbiased mass 
spectrometry approach, we determined which EGF induced phosphorylation events were 
sensitive to RSK inhibition.  Functional analysis of the changes in the phospho-proteome upon 
RSK inhibition led us to the discovery of RSK regulation of p38 and ERK5 signaling.  We also 
find that RSK inhibition decreases phosphorylation of MEKK3, a master regulator of both ERK5 
and p38.  Either RSK inhibition or mutation of the putative RSK target sites increases activation 
of MEKK3 kinase.  We propose that EGF stimulation causes a transient activation of p38 which 
is terminated by RSK directly phosphorylating and inhibiting MEKK3. 
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Results 
Phosphoproteomic analysis using BI-D1870 identifies RSK specific substrates 
 To understand the RSK contribution to the phosphoproteome regulated by the EGFR-
ERK signaling cascade, we chose a model system whose proliferation relied on EGF.  MCF10A 
cells are non-tumorigenic breast epithelial cells that express EGFR and display robust activation 
of both ERK and PI3K kinase signaling in response to EGF.  We stimulated MCF10A cells with 
10ng/mL EGF in the absence or presence of the RSK catalytic inhibitor BI-D1870.  Cells were 
lysed and the lysates were normalized using the Bradford protein assay.  Proteins were 
fragmented using trypsin digestion.  Peptides obtained from cell lysates treated with BI-D1870 
were labeled with heavy formaldehyde groups whereas the control peptides from DMSO treated 
cells were labeled with light peptides.  Samples were combined, enriched for phospho-peptides 
using Titanium dioxide and analyzed with liquid chromatography-mass spectrometry (LC-
MS/MS).  In the final analysis of the mass-spectras we identified 7605 unique phosphorylated 
peptides.   
We then plotted Log2 (BI-D1870/DMSO) ratios for each phospho-peptide.  A negative 
ratio for a phospho-peptide means that the phosphorylation was decreased by BI-D1870 
treatment, suggesting that these events required RSK activity.  A positive ratio means that BI-
D1870 treatment increases the abundance of these phospho-proteins (Figure 3.1).  To validate 
our experimental approach, we first determined the ability of BI-D1870 treatment to reduce the 
phosphorylation of previously validated RSK targets.  Accordingly, SOS1 Ser1134, RAPTOR 
Ser721, YBX Ser102 and BAD Ser75 (equivalent of mouse Ser112) were all reduced 2 fold or 
more in response to BI-D1870 treatment.  (Table 3.1) 
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Figure 3.1 RSK regulates EGF induced phospho-proteome.  MCF10A cells were 
stimulated with EGF in the presence or absence of the RSK inhibitor BI-D1870.   For 
each phospho-peptide the change in phosphorylation status due to inhibitor treatment was 
quantified and plotted as a Log2 ratio.  A negative ratio indicates reduction in abundance 
of a certain phospho-peptide in response to BI-D1870 treatment whereas positive ratio 
indicates increased phosphorylation in response to BI-D1870 treatment.  Dashed lines are 
Log2 ratios of 1 and -1, which represent two fold increase or decrease in phosphorylation, 
respectively. 
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Table 3.1 Analysis of the phospho-proteomic data for known substrates of kinases validates that 
BI-D1870 specifically inhibits RSK activity.  Phosphorylation of validated RSK substrates but 
not substrates of the related AKT and S6K is decreased by BI-D1870 treatment.  BI-D1870 also 
does not non-specifically reduce phosphorylation of PLK1 substrates. 
Protein Phosphosite Fold Different Substrate of 
SOS1 Ser1134 Down 4.53 fold RSK 
RAPTOR Ser721 Down 2.36 fold RSK 
BAD Ser75 Down 2.38 fold RSK 
YBX-1 Ser102 Down 8.17 fold RSK, AKT 
BAD Ser99 Up 1.02 fold AKT, S6K 
rpS6 Ser240 Down 1.14 fold S6K 
RICTOR Ser21 Down 1.16 fold S6K 
PIKFYVE Ser318 Up 1.1 fold AKT 
PRAS40 Thr246 Down 1.14 fold AKT 
RAC1 Ser71 Down 1.03 fold AKT 
MST2 Ser316 Up 1.1 fold PLK1 
ROCK2 Ser1133 Up 1.12 fold PLK1 
 
A caveat of using ATP competitive catalytic inhibitors of protein kinases is non-specific 
inhibition of other kinases due to similarities in their ATP binding pockets.  Thus we monitored 
the effect of BI-D1870 treatment on targets of the related AKT and S6K.  We found that despite 
the reduction in BAD Ser75 phosphorylation, BAD Ser99 (the equivalent of mouse Bad Ser136) 
phosphorylation, which is targeted mainly by AKT and S6K, was not affected by BI-D1870 
treatment.  Phosphorylation of rpS6 Ser240-Ser244 and RICTOR Ser21, which are S6K targets, 
and PIKFYVE Ser 318, PRAS40 Thr246 and RAC1 Ser71 which are AKT targets were also not 
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altered.  Altogether these results suggest that BI-D1870 does not inhibit AKT or S6K.  Polo like 
kinase (PLK) can be inhibited by BI-D1870 in vitro, yet at a concentration that is more than 10 
fold over the concentration required for RSK inhibition (Sapkota et al., 2007).  To determine if 
BI-D1870 inhibits phosphorylation of PLK substrates in cells, we also monitored the changes in 
phosphorylation of known PLK substrates.  Mammalian sterile 20 like kinase 2 (MST2) Ser316 
and Rho associated kinase 2 (ROCK2) Ser 1133 phosphorylation events, both of which have 
been shown to be mediated by PLK (Lowery et al., 2007; Mardin et al., 2011), remained 
unaltered by BI-D1870, suggesting BI-D1870 does not interfere with PLK activity under our 
experimental conditions. 
Bioinformatics analysis of RSK phospho-proteome uncovers RSK regulation of p38 and ERK5. 
To gain a global understanding of the RSK regulated phospho-proteome, we tested the 
statistical significance of enrichment for signaling pathways in our data set.  We performed the 
analysis with phospho-proteins whose phosphorylation levels were differentially regulated by 
RSK inhibition by a factor of 2.  Of the 7605 phosphorylation we found that 607 of them were 
differentially regulated by the drug treatment: Phosphorylation of 427 peptides was down 
regulated and 180 peptides were up-regulated.  Functional clustering of the phospho-proteins 
using the Database for Annotation, Visualization and Integrated Discovery (DAVID) (Huang da 
et al., 2009) into KEGG pathways revealed that RSK regulated proteins were statistically 
significantly enriched for a variety of biological processes (Figure 3.2).  Underlying the 
importance of RSK in growth factor signaling, phospho-proteins down regulated with BI-D1870 
belonged to EGFR and Insulin Signaling.  RSK regulated proteins were also enriched for 
migration pathways such as adherens junction signaling and regulation of actin cytoskeleton 
regulatory pathways, which is consistent with the idea that the ERK-RSK signaling contributes 
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to cell migration through not only regulating transcription factors but also regulating cytoplasmic 
proteins(Mendoza et al., 2011b; Woo et al., 2004). 
Surprisingly, RSK inhibition resulted in upregulation of phosphorylation of proteins that 
clustered into the MAPK pathway.  Activation loop phosphorylation of p38 and ERK5 were both 
increased in response to BI-D1870 treatment (Figure 3.3). We also observed upregulation of Tau 
phosphorylation on Ser396 and Thr403, which are direct targets of p38 in vitro (Reynolds et al., 
2000).  The activating phosphorylation on MSK2, Ser343 and Ser347, were also increased.  Heat 
shock protein 27kD phosphorylation and TAB3 phosphorylation both of which are known to be 
regulated by the p38 activated MK2 were also up-regulated (Butt et al., 2001; Mendoza et al., 
2008).  These data demonstrates that p38 and majority of its downstream signaling components 
were activated by RSK inhibition. 
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Figure 3.2 RSK regulates multiple signaling pathways.  Proteins whose phosphorylation 
was altered two fold or more in response to BI-D1870 were used for functional clustering 
using DAVID.  Proteins were clustered into KEGG signaling pathways.  Signaling 
pathways that show statistically significant enrichment in the phospho-proteomic data 
sets with p-value of 0.1 or less are depicted above. 
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Figure 3.3 BI-D1870 treatment reveals RSK mediated crosstalk to p38 Signaling. 
Phospho-proteins grouped in the MAPK signaling pathway cluster in the analysis in 
Figure 3.2 are depicted in this figure.  Fold changes in phosphorylation in response to 
RSK inhibitor treatment is shown with arrows pointing to the direction of change. 
 
 
 
 
 
 
 
 
 
 
 
 
88 
 
In order to validate upregulation of p38 and ERK5 signaling by RSK inhibition, we 
utilized western blotting.  EGF stimulation of MCF10A cells caused a small increase in p38 
activation loop phosphorylation which was dramatically increased when cells were pre-treated 
with BI-D1870.  To determine if the increase in p38 activity was due to a potential off target 
effect of BI-D8170, we used a structurally different RSK inhibitor, SL0-101 (Smith et al., 2005).  
Similar to BI-D1870, SL0-101 treatment also dramatically increased the p38 phosphorylation in 
response to EGF.  This increase was accompanied by a reduced gel mobility of MSK2 and ERK5 
suggesting that these kinases were also hyperphosphorylated.  Taken together we conclude that 
RSK activation downstream of EGF is responsible for reducing p38 and ERK5 signaling 
pathways (Figure 3.4). 
RSK regulates MEKK3 phosphorylation and kinase activity 
One possible mechanism of RSK mediated MEKK3 inhibition may be through inhibition 
of RAC1, the activator of MEKK3.  AKT phosphorylates RAC1 on Ser71 and inhibits GTP 
binding by RAC1, which may lead to reduction in p38 signaling.  Because AGC kinases can 
redundantly phosphorylate certain substrates we asked whether RSK inhibition resulted in 
decreased RAC1 phosphorylation.  Similar to other AKT substrates whose phosphorylation did 
not change in response to BI-D1870 treatment in our data set, we also found RAC1 Ser71 
phosphorylation is not changed (Table 3.1). 
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Figure 3.4 RSK inhibition enhances EGF stimulated ERK5 and p38 signaling.  MCF10A 
cells were stimulated with EGF (10ng/mL) in the presence or absence of the indicated 
inhibitors for 10 min.  Treatment with either RSK inhibitor enhances EGF stimulated p38 
activation loop phosphorylation as well as ERK5 phosphorylation. Western blots are 
representative of two independent experiments.   
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In order to find putative RSK substrates involved in regulating p38 and ERK5 signaling 
we searched for peptides whose phosphorylation sites resided in the in the canonical RSK target 
motif Lys/Arg-X-Arg-X-X-Ser/Thr.  Out of 7605 phospho-peptides 380 of them contained a 
putative consensus RSK phosphorylation site.  51 phospho-peptides were down regulated 2 fold 
or more in response RSK inhibition.  Among these proteins MEKK3 Ser337 phosphorylation 
was decreased 6 fold upon BI-D1870 treatment (Table 3.2).   
Table 3.2 Top ten proteins whose basophilic phosphorylation showed highest reduction 
in response to BI-D1870 treatment 
Official Gene Symbol Site Fold inhibition 
WDR62 Thr50 15.9 
MDB4 Ser318 15 
AHNAK Ser315 9.8 
DDI2 Ser194 9.5 
LRRC41 Ser105 9.5 
FAM83H Ser292 8.8 
NCBP1 Ser22 7.4 
MAP3K3 Ser337 6.0 
LAD1 Ser38 5.8 
SIPA1L1 Ser1508 5.7 
 
Phospho-AKT substrate antibody labeling of immuno-precipitated MEKK3 was reduced 
upon treating cells with BI-D1870 (Figure 3.5).  Additionally, EGF stimulation induced a 
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MEKK3 mobility shift, which was abrogated by BI-D1870 and SL0-101 treatment in MCF10A 
cells, suggesting that RSK regulates EGF driven MEKK3 phosphorylation (Figure 3.4).   
To identify the function of RSK phosphorylation of MEKK3, we aligned the amino-acid 
sequence of MEKK3 with other MAPKKKs.  MEKK3 Ser337 aligned with BRAF Ser429, 
which is phosphorylated by AKT and PKA (Figure 3.6) (Guan et al., 2000; Konig et al., 2001).   
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Figure 3.5 BI-D1870 treatment reduces MEKK3 phosphorylation.  HEK293E cells were 
transiently transfected with HA-MEKK3.  MEKK3 was immunoprecipitated with anti-
HA antibodies from cells treated with or without BI-D1870 and blotted with the phospho-
AKT substrate antibody (pAS). Western blots are representative of two independent 
experiments 
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Figure 3.6 BRAF Ser429 aligns with MEKK3 Ser337.  Alignment was performed using 
ClustalW.  BRAF phosphorylation of Ser429 is inhibitory for BRAF kinase activity. “:” 
indicates similarity, “*” indicates identical amino acids. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
94 
 
Phosphorylation of Ser429 reduces BRAF activity in vitro, suggesting that MEKK3 
Ser337 phosphorylation may also reduce MEKK3 activity.  Further analysis of the phospho-
proteomic data revealed MEKK3 Ser166 phosphorylation is also down regulated 1.8 fold upon 
RSK inhibition.  To test, if RSK activity inhibited MEKK3, we immunoprecipitated exogenously 
expressed HA-MEKK3 from HEK293 cells treated with or without BI-D1870 and measured 
MEKK3 autophosphorylation as well as phosphorylation of one of its downstream targets 
MKK3.  To prevent interference from MKK3 autophosphorylation, we mutated the catalytic Lys 
in the ATP binding pocket of MKK3 to an Arg (K/R).  MEKK3 phosphorylation of MKK3-K/R 
and MEKK3 autophosphorylation were both enhanced when cells were treated with BI-D1870 
suggesting that RSK activity inhibits MEKK3 (Figure 3.7).  To determine whether RSK 
inhibition of MEKK3 was due to MEKK3 phosphorylation of Ser337 and Ser116, we measured 
the kinase activity of wild-type (WT) and S337A, S166A or the S337 and S166A (AA) mutants 
of MEKK3.  Mutating either or both phosphorylation sites to Ala increased MEKK3 activity 
suggesting that RSK inhibits MEKK3 activity by regulating the Ser337 and Ser166 
phosphorylation (Figure 3.7). 
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Figure 3.7 RSK inhibition and mutation of the RSK phosphorylation site activates MEKK3 
activity in vitro. Wildtype (WT) or mutant MEKK3 was immunoprecipitated from HEK293E 
cells treated with or without BI-D1870.  MEKK3 was then incubated with bacterially purified 
kinase dead GST-MKK3 and radioactive 32P-ATP.  MEKK3 kinase activity was assessed by 
measuring MEKK3 autophosphorylation and GST-MKK3 phosphorylation. Western blots are 
representative of two independent experiments. 
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Conclusions and Future Directions 
Our phospho-proteomic screen revealed RSK mediated feedback inhibition of p38 and 
ERK5 pathways through inactivation of MEKK3.  Given that MEKK3 phosphorylation sites 
follow the consensus RSK target motif, it is highly likely that RSK directly regulates 
phosphorylation of MEKK3.  However, without testing RSKs ability to directly phosphorylate 
MEKK3 in vitro, we cannot rule out the possibility of an intermediate kinase to regulate MEKK3 
phosphorylation.  We also need to identify which RSK isoform is responsible for the MEKK3 
phosphorylation as BI-D1870 and SL0-101 inhibit multiple RSK isoforms (Bain et al., 2007). 
Mutation of the putative RSK phosphorylation sites increase MEKK3 activity, however 
the underlying mechanism is not known.  Mutation of these sites does not alter 14-3-3 binding to 
MEKK3 (Matitau and Scheid, 2008) suggesting RSK does not modulate 14-3-3 binding to 
MEKK3.  MEKK3 and MEKK2 activation is known to involve homodimerization (Zhang et al., 
2006a).  Thus, RSK mediated inhibition of MEKK3 activity may involve regulation of homo or 
heterodimerization.  Alternatively, MEKK3 phosphorylation may differentially regulate its 
membrane recruitment.   
Delineating the mechanism of how EGF activates MEKK3 will also be important as this 
may give us clues into how RSK can regulate MEKK3.  Expression of active form of H-RAS in 
MCF10A increases GTP loaded RAC correlates with an increase in MKK3, MKK6 and p38 
phosphorylation, suggesting that RAS can activate RAC-MKK3/MKK6-p38 signaling axis (Shin 
et al., 2005a).  Extracellular matrix engagement and EGF stimulation of also activates RAC in an 
EGFR and PI3K dependent manner (Dise et al., 2008; Marcoux and Vuori, 2003; Tamas et al., 
2003).  Thus, EGF may activate MEKK3 by activating RAC downstream of RAS and PI3K to 
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activate MKK3/MKK6-p38 signaling pathway.  This hypothesis can be tested by determining the 
ability of cells to activate p38 in response EGF in the presence or absence PI3K and RAC 
inhibitors or by introduction of dominant negative RAC. 
 From a physiological perspective, it is also important to understand the function of the 
RSK regulation of p38 and ERK5 pathways.  In our preliminary analysis we observed that 
MEKK3 null mouse embryonic fibroblasts (MEFs) have a higher proliferation rate than wild 
type MEFs suggesting that MEKK3 activity may reduce proliferation (data not shown).  
Additionally, upon depriving the cells of serum, wild type MEFs did not increase in number 
whereas; MEKK3 null MEFs continued to proliferate.  This can either mean that MEKK3 is a 
negative regulator of cell proliferation or is a positive regulator of cell death.  The latter 
explanation seems more plausible as p38 null MEFs are also resistant to serum deprivation 
induced apoptosis (Porras et al., 2004).  It is possible that under normal growth conditions, RSK 
phosphorylates and inhibits MEKK3.  This can then restrict p38 activation and therefore 
inappropriate timing of apoptosis (Figure 3.8).  When cells are serum deprived, RSK can no 
longer phosphorylate MEKK3.  Hypo-phosphorylated MEKK3 may then activate p38 signaling 
which would enhance cell death.  MEKK3 also activates NFkB signaling which leads to 
increased cytokine production (Yang et al., 2001).  In our phospho-proteomic data set we did not 
observe any changes in phosphorylation of the NFkB signaling components.  However, this may 
be due to timing of the screen as MEKK3 regulates both immediate transient NFkB activation as 
well as the late and sustained NFkB activation (Yamazaki et al., 2009).  The finding that RSK 
mediated MEKK3 phosphorylation regulates NFkB signaling would constitute another example 
of signaling crosstalk.  Currently we are working on reconstituting MEKK3 null MEFs with WT 
MEKK3 or RSK phosphorylation deficient mutant of MEKK3 to test these hypotheses. 
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Figure 3. 8 Model of how RSK phosphorylation regulates MEKK3 function and 
downstream signaling.  Upon EGF stimulation RSK phosphorylates and inhibits 
MEKK3.  This prevents p38 and ERK5 activation.  However, how EGF activates p38 and 
ERK5 and how RSK mediated inhibition of MEKK3 regulates downstream biological 
processes need further investigation. 
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CHAPTER 4 
IDENTIFICATION AND CHARACTERIZATION OF NEW TARGETS OF THE ERK-
RSK PATHWAY 
Work presented in this chapter is not published.  ERK2 D and ERK2 DEF domain 
expressing MCF10A cells were generated in collaboration with Didem Ilter.  Sample preparation 
and the data analysis for mass spectrometry experiments were carried out by Dr. Bo Zhai and Dr. 
Steve Gygi.  Didem Ilter is carrying out transcriptome analysis to be correlated with the mass 
spectrometry data.  Dr. Michal Nageuic is currently following up on the MELK kinase.   
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Introduction 
ERK is a Ser/Thr Kinase and has been shown to phosphorylate more than 100 proteins in 
regulation of various biological processes (Yoon and Seger, 2006).  The substrate specificity of 
ERK kinases is achieved by substrate localization, scaffolding, phosphorylation motifs and 
docking interaction.  ERK phosphorylates proteins with the target motif (Pro-X-Ser/Thr-Pro).  
ERK also utilizes two domains on substrate proteins.  Docking site for ERK FXFP (DEF) 
domains are small amino acid stretches of Phe-X-Phe-Proline. These domains have been 
identified on ERK substrates involved in migration such as Vinexin (Mitsushima et al., 2004), 
Paxillin(Ishibe et al., 2003) and WAVE-2 (Mendoza et al., 2011b), and transcription such as 
FRA-1, ELK-1 and FOS (Dimitri et al., 2005; Murphy et al., 2002; Shin and Blenis, 2010).  The 
other substrate recognition domain is the D domain, which consists of Lys/Arg-Lys/Arg 
followed by a stretch of 2-6 amino acids then with two hydrophobic residues separated by one 
amino acid.  ERK interacts with DUSP, RSKs and MSKs through D domains on these substrates 
(Figure 4.1).  Importantly, mutation of residues on ERK responsible for interacting with DEF 
and D domains greatly reduces the ability of ERK to phosphorylate its substrates in vitro and in 
cells.  For example, ERK DEF domain binding mutant Tyr-261-Ala (Y261A) cannot 
phosphorylate FOS but can still phosphorylate RSK, while ERK D domain binding mutant Asp-
319-Asn (D319N) cannot phosphorylate RSK but is able to phosphorylate FOS (Dimitri et al., 
2005). 
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Figure 4.1 Spatially separate docking domains regulate ERK phosphorylation of distinct 
substrates 
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Mutation of these spatially separate docking domains on ERK2 in MCF10A cells causes 
distinct cellular phenotypes.  Expression of the ERK2 D319N mutant increases cellular 
migration and invasion along with enhanced expression of epithelial to mesenchymal transition 
(EMT) markers and increased stem cell makers.  ERK2 D319N induced EMT is FRA1 
dependent as silencing of this DEF domain target transcription factor reduces EMT (Shin and 
Blenis, 2010).  On the other hand expression of the ERK2 Y261A mutant, which cannot directly 
phosphorylate and stabilize FRA1, results in proliferation (Dr. Chris Dimitri unpublished data) 
but not EMT, invasion and migration.  Taken together these data suggest that signaling 
downstream of spatially separate ERK2 docking domains mediate distinct cellular phenotypes 
through activation of different group of signaling proteins.   
To test this hypothesis we utilized an unbiased mass-spectrometry based approach to 
study the phospho-proteome downstream of ERK DEF signaling (ERK2 D319N) and ERK2 D 
signaling (ERK2 Y261A).  We had two major goals 1) to identify novel ERK and RSK 
substrates 2) to understand crosstalk between ERK and other signaling pathways in the context 
of these mutants.  We found many phosphorylation events were differentially regulated by ERK2 
DEF and ERK2 D signaling in response to EGF at different time points.  Classification of the 
phosphorylation motifs revealed a decrease in phosphorylation of known RSK substrates in 
ERK2 DEF cells.  We further characterized phosphorylation of two proteins, nuclear interacting 
partner of ALK (NIPA) and RALBP1 associated EPS domain containing protein 1 (REPS1).  
Reduced RSK substrate phosphorylation correlated with reduced RSK2 phosphorylation in 
ERK2 DEF cells but RSK1 phosphorylation was similar in both ERK2 DEF and ERK2 D cells.  
We also observed that ERK2 D cells had higher mTORC1 and AKT3 pathway activation 
compared to ERK2 DEF cells.  Further analysis of the phospho-proteomic data set and 
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characterization of these new ERK targets will certainly enhance our understanding of the ERK-
RSK signaling pathway and how it interacts with other signaling cascades. 
Results 
Phospho-proteomic approach identifies ERK2 D and ERK2 DEF signaling specific substrates 
To determine the phospho-proteome regulated by ERK2 D and DEF signaling we 
generated MCF10A cells with endogenous ERK2 knockdown followed by a rescue with ERK2 
D signaling (ERK2 Y261A) or ERK2 DEF signaling (ERK2 D319N).  These cells were 
stimulated with or without EGF for 10 or 60 minutes.  Due to the complexity of this system, 
instead of the SILAC approach we used in defining the mTOR phosphoproteome (Yu et al., 
2011), we used reductive dimethylation combined LC-MS/MS (Khidekel et al., 2007; Villen and 
Gygi, 2008).  We labeled and combined phospho-peptides obtained from serum starved or EGF 
stimulated cells.  This combination was carried out for both the ERK2 D and ERK2 DEF cells 
which resulted in 4 distinct EGF regulated phospho-proteomes: 1) 10 min EGF in ERK2 DEF 
cells, 2) 10 min EGF in ERK2 D cells 3) 60 min EGF in ERK2 DEF cells and 4) 60 min EGF in 
ERK2 D cells (Figure 4.2).  In the 10 minute datasets we identified a total of 12603 phospho-
peptides, 5623 of which was identified in both ERK2 DEF and ERK2 D screens.  In the 60 
minutes datasets we identified a combined 9727 phosphopeptides 4439 of which were identified 
in both ERK2 DEF and ERK2 screens. 
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Figure 4.2 Schematic representation of generating phosphoproteomic data in ERK2 D and 
DEF cells 
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Because ERK2 DEF cells cannot signal to RSK, we hypothesized that RSK substrate 
phosphorylation in response to EGF would be reduced in these cells.  Accordingly, 
phosphorylation of several established RSK substrates were increased to greater extend in ERK2 
D cells than ERK2 DEF cells, 10 minutes following EGF stimulation.  These phosphorylation 
events included, EIF4B Ser420, GSK3A Ser21 and rpS6 Ser235-Ser236 (Table 4.1).  In addition 
to these known targets, we identified REPS1 Ser709 and NIPA Ser407 phosphorylation to be 
specifically increased in ERK2 D cells suggesting these may be RSK targets.  On the other hand, 
we could not identify any known effectors of ERK2 DEF signaling in our cells either at 10 
minutes or 60 minutes following EGF stimulation in cells.  This might be due to the fact that 
most of the known ERK2 DEF domain targets are low abundance transcription factors. 
Table 4.1 ERK2 D but not ERK2 DEF signaling cells promote RSK substrate 
phosphorylation in response to EGF stimulation.  Values in the table below 
are fold induction in response to EGF stimulation for each time point and each 
mutant cell line. N/A: Not available. 
Mutant ERK2 DEF ERK2 D ERK2 DEF ERK2 D 
Time (min) 10 10 60 60 
Substrate     
EIF4B Ser420 1.16 5 N/A N/A 
GSK3A 1.21 2.21 1.05 1.63 
RPS6 Ser235 1.04 8.08 0.67 0.87 
RPS6 Ser236 1.35 7.69 0.64 1.15 
REPS1 Ser709 1.39 2.83 N/A N/A 
NIPA Ser407 1.47 5.05 N/A N/A 
 
Validation of ERK2 D signaling targets 
We determined to validate two of the phosphorylation sites we found in our screens.  
REPS1 is a highly phosphorylated protein that associates with Ral GTP binding protein 
(RALBP1) and intersectin (Dergai et al., 2010; Yamaguchi et al., 1997).  To determine if our 
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phospho-proteomic approach identified the correct phosphorylation site on REPS1, we expressed 
either WT or S709A mutant of FLAG tagged REPS1 in HEK 293 cells.  When immune-
precipitated from cells western blot analysis revealed that only WT but not S709A REPS1 was 
labeled with pAS antibody suggesting REPS1 is phosphorylated on Ser709 in cells (Figure 4.3).   
To determine if this phosphorylation depends on ERK and downstream RSK activity, we 
transfected HEK 293 cells with WT REPS1, serum starved cells and stimulated with Phorbol 12-
myristate 13-acetate (PMA).  REPS1 phosphorylation was detected only in cells stimulated with 
PMA and not in starved cells.  Furthermore, REPS1 phosphorylation was sensitive to MEK 
inhibitor U0126 and RSK inhibitor BI-D1870, suggesting ERK and RSK mediate Ser709 
phosphorylation (Figure 4.4). 
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Figure 4.3 REPS1 is phosphorylated at Ser709 in cells.  HEK293E cells were transfected 
with Wildtype (WT) or S709A mutant of FLAG tagged REPS1.  REPS1 was 
immunoprecipitated with FLAG antibody conjugated beads and blotted with the 
phospho-AKT substrate antibody (pAS). 
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Figure 4.4 REPS1 Ser709 Phosphorylation requires RSK activity. HEK293E cells were 
transfected with FLAG-REPS1.  Cells were stimulated with PMA (100ng/mL) in the 
presence or absence of MEK and RSK inhibitors, U0126 and BI-D1870. Tx: transfection 
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Another substrate phosphorylated downstream of ERK D domain was NIPA.  NIPA is a 
constitutively nuclear protein that regulates cyclin B abundance and cell cycle(Bassermann et al., 
2007).  We identified S407 phosphorylation downstream of ERK D domain signaling.  The 
phosphorylation site lied in the consensus RSK target motif suggesting that RSK may 
phosphorylate NIPA.  To test this, we purified GST tagged NIPA from bacterial cells to use it as 
a substrate in in vitro kinase assay.  When HA tagged RSK was immunoprecipitated from PMA 
stimulated cells, but not from PMA stimulated cells in the presence of U0126, RSK was able to 
phosphorylate NIPA in vitro (Figure 4.5). 
We also found identified phosphorylation of MELK Ser415 and Ser409 downstream of 
ERK2 DEF signaling.  MELK is a kinase involved in stem cell maintenance and function and is 
over-expressed in a variety of cancers (Gray et al., 2005; Nakano et al., 2005).  Unfortunately, 
we did not identify the same phosphopeptides in the ERK2 D domain signaling cells, which 
prohibits any conclusions about whether MELK is specifically activated by ERK2 DEF 
signaling.  However, it is important to note that MELK has a very high stringency ERK DEF 
domain on Ser442.  Most ERK2 DEF domains are located  about 20 amino acids downstream of 
the ERK phosphorylation site on substrate proteins (Cargnello and Roux, 2011).  The presence of 
the ERK DEF domain 33 and 27 amino acids downstream of the ERK2 phosphorylation sites we 
identified suggests that MELK may be a de novo ERK2 DEF substrate. 
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Figure 4.5 RSK1 phosphorylates NIPA in vitro.  HEK293T cells were transfected with 
avian HA tagged RSK1 and stimulated with or without PMA in the presence or absence 
of U0126.  RSK1 was immunoprecipitated with HA-antibodies and used as the kinase to 
phosphorylate bacterially purified GST-NIPA in the presence of radioactively labeled 
32P-ATP. Western blots are representative of two independent experiments. 
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ERK2 D and DEF signaling may differentially regulate distinct crosstalk mechanisms. 
Further analysis of the ERK2 D and DEF phosphoproteomes revealed that rpS6 Ser240 
phosphorylation, which is carried out exclusively by S6K, was also up-regulated specifically in 
ERK2 D cells but not ERK2 DEF cells upon EGF stimulation.  We hypothesized that 
upregulation of S6K might reflect increased mTORC1 activity in ERK2 D cells.  In support of 
this idea 4EBP1 Ser65-Ser70 phosphorylation were also enhanced in ERK2 D cells.  Increase in 
the S6K signaling at the 10 minute time point was specific to mTORC1 arm of PI3K signaling as 
AKT2 and AKT3 hydrophobic motif phosphorylation, which indicate AKT activity, as well as 
AKT substrate PRAS40 Thr246 phosphorylation were all stimulated to similar extends in both 
cell lines after 10 minutes.  On the other hand, these phosphorylation events were sustained only 
in ERK2 D signaling but not ERK2 DEF signaling cells 60 minutes following EGF stimulation.  
Neither IRS1 Ser636 nor RICTOR Ser21 phosphorylation was differentially regulated at the 60 
minute time point suggesting that differential regulation of S6K mediated feedback signaling to 
PI3K could not explain the observed sustained AKT activation in ERK2 D cells (Table 4.2). 
Table 4.2 mTORC1 signaling in 10 minute and AKT signaling at 60 minute time 
points are enhanced in ERK2 D cells as compared to ERK2 DEF cells. 
Mutant ERK2 DEF ERK2 D ERK2 DEF ERK2 D 
Time(min) 10 10 60 60 
Substrate     
RPS6 Ser240 1.06 5.33 0.62 0.91 
EIF4EBP1 Ser70 1.38 2.01 0.84 1.1 
EIF4EBP1 Ser65 1.31 2.15 0.93 1.09 
AKT2 Ser474 3.17 4.73 1.17 1.83 
AKT3 Ser 472 2.76 5.72 1.17 2.3 
PRAS40 Thr246 2.05 2.82 0.53 4.59 
IRS1 Ser636 N/A N/A 3.15 2.97 
RICTOR Ser21 0.92 0.92 0.95 0.9 
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ERK2 D signaling also increased MSK2 Ser343-Ser347 phosphorylation, in line with the 
hypothesis that ERK2 can activate both RSK and MSKs in the context of EGF stimulation 
(Table 4.3).  Surprisingly, we also detected a very high level of induction of RSK1 Ser363 and 
Ser369 phosphorylation in each cell line suggesting that the ERK1 activity may be sufficient to 
activate RSK1 in the absence of ERK2 D domain signaling.  These phosphorylation events were 
also present at the 60 minute time point suggesting sustained RSK1 activity.  Interestingly, RSK2 
phosphorylation on Ser715 was only induced in ERK2 D signaling cells.  This is an 
autophosphorylation site by which RSK phosphorylation induces RSK dissociation from ERK.  
The finding that RSK2 but not RSK1 phosphorylation is differentially regulated between these 
two cell lines suggests that ERK1 activity may be sufficient to induce RSK1 but not RSK2 
activity.  Analysis of SOS1 phosphorylation revealed that this phosphorylation was similarly 
induced between ERK2 D and ERK2 DEF cell lines.  Taken together with the data obtained from 
BI-D1870 treated cells, these data suggest that SOS1 Ser1134 may be a RSK1 specific targets 
but this hypothesis should be tested. 
Table 4.3 Phosphorylation of MSK2 and RSK2 are enhanced in ERK2 D cells 
Mutant ERK2 DEF ERK2 D ERK2 DEF ERK2 D 
Time(min) 10 10 60 60 
Substrate     
MSK2 Ser343 1.3 3.73 NA NA 
MSK2 Ser347 1.12 5.05 NA NA 
RSK1 Ser363 7.05 19.26 1.91 2.21 
RSK1 Ser369 7.11 19.26 1.91 2.21 
RSK2 Ser415 1.36 1.7 0.98 0.97 
RSK2 Ser715 1.14 2.3 N/A N/A 
SOS1 Ser1134 15.66 26.84 2.18 3.28 
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Conclusions and Future Directions 
 In this chapter we tried to identify targets of ERK2 D and ERK2 DEF signaling pathways 
that can help us explain the different biological processes regulated downstream of these 
signaling axis.  We found that ERK2 D cells increased AKT3 signaling at the 60 minute and 
mTORC1-S6K1 signaling at the 10 minute time points.  We could not identify differential 
phosphorylation of any known regulators of AKT signaling that could explain the increased 
AKT3 phosphorylation in ERK2 D signaling cells.  This suggests that there may be a novel 
crosstalk mechanism between ERK2 D and AKT signaling to be discovered. However, increased 
S6K1 signaling maybe explained by increased RAPTOR Ser722 phosphorylation, which is 
known to activate mTORC1 signaling to downstream S6K1 and 4EBP1. 
 ERK2 D signaling cells proliferate at a much faster rate than ERK2 DEF signaling cells.  
One hypothesis is ERK2 D cells may be proliferating faster due to parallel activation of 
mTORC1-S6K1 signaling, which is absent in ERK2 DEF signaling cells.  Alternatively, RSK2 
activation in ERK2 D cells may drive NIPA phosphorylation leading to more efficient cell cycle.  
It is important to note that MSK2 phosphorylation on Ser343 and Ser347 were also specifically 
up-regulated in ERK2 D cells.  Despite the evidence that RSK can phosphorylate NIPA in vitro, 
it is also possible that in ERK2 D cells, active MSK2 is phosphorylating NIPA.  Given that both 
MSK2 and NIPA are constitutively nuclear proteins, the hypothesis that MSK2 phosphorylates 
and regulates NIPA should be tested.  
 We also found that RSK mediated feedback and crosstalk to SOS1 was intact in both cell 
lines possibly due to unaltered RSK1 activation in both cell lines.  This suggests that differential 
regulation of RSK mediated feedback may not be sufficient to explain the different biological 
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processes regulated downstream of ERK2 D and ERK2 DEF signaling axes.  On the other hand, 
RSK2 was specifically phosphorylated downstream of ERK2 D signaling.  It is possible that 
RSK isoforms may be getting differentially regulated by ERK isoforms, however this hypothesis 
requires more experimentation to be validated.  A major caveat of our phospho-proteomics 
analysis is that direct comparison between different cells lines in terms of fold induction of 
phospho-peptides may not be accurate.  This is because of the fact that except for the EGF 
starved and stimulated samples, all other samples were processed and analyzed separately for 
each mutant cell line and each time point suggesting that there may be experimental errors 
between each data set.  Therefore, more accurate comparisons of signaling cascades downstream 
ERK2 D and ERK2 DEF signaling would require western blot validation or a new phospho-
proteomic approach. One such approach is multiplexing where more than two samples can be 
simultaneously processed, digested and labeled (Dephoure and Gygi, 2012). 
Because expression of ERK2 D319N, which is defective in RSK activation, is sufficient 
to induce EMT, it is possible that RSK activity is dispensable for ERK2 DEF signaling induced 
EMT.  On the contrary, expression of the oncogenic RAS V12 and B-RAF V600E  in MCF10A 
cells require RSK activity for executing an EMT-like transcriptional profile as RSK inhibition 
blocks both RAS and RAF induced EMT (Doehn et al., 2009; Smolen et al., 2010).  Our data 
suggest in ERK2 D319N cells RSK1 activity may be sufficient to drive event that require RSK 
activity, yet this hypothesis should also be tested further. 
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CHAPTER 5 
 DISCUSSION AND FUTURE DIRECTIONS 
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Crosstalk and Cell Type Specificity 
 Despite being thought as linear cascades, over a decade of work has shown that there is 
intricate crosstalk between growth, stress and metabolic pathways (Mendoza et al., 2011a).  In 
regulation of complex biological processes such as multicellular development, it is not surprising 
that the organism requires interpretation of environmental signals not only at the organismal but 
also at the cellular level.  Therefore, it is important to note that the extent of crosstalk between 
each signaling cascade may depend on the developmental stage of the cell, the cell’s genetic 
makeup or the extracellular environment that surrounds the cell.  All these factors not only 
determine how each signaling pathway is wired in different types of cells, but also determine 
how each signaling cascade will respond to perturbations to the parallel pathways.  In our work 
we focused mostly on breast epithelial cell lines because they have acquired a small number of 
mutations and this provides a tractable model system.  The next stage of these studies would be 
to understand whether the crosstalk and feedback mechanisms we identified are relevant to 
different cell lines and if not determine why.   
For example, we found that AKT and PIKfyve regulate EGFR degradation in HMECs 
and MCF10A cells.  However, AKT activity was not required for EGFR degradation in MDA-
MB-468 cells (not shown).  There are four different reasons why AKT activity would not be 
required for EGFR degradation in MDA-MB468 cells: 1) PIKfyve may be regulated related by 
kinases, such as SGK, S6K or RSK in this experimental system.  2) EGF induced a very small 
amount of EGFR degradation.  This may be because EGFR is amplified at the genomic locus of 
these cells and highly over-expressed compared to HMECs and MCF10A cells.  Therefore, even 
at very high concentrations of EGF stimulation, the endocytic capacity reaches saturation leading 
to reduced EGFR degradation.  3) MDA-MB468 cells also do not have functional PTEN.  This 
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may cause a different steady state concentration of each phosphoinositide, which can no longer 
be regulated by AKT. 4) In our western blot analysis we noticed that PIKfyve from MDA-
MB468 cells undergoes a mobility shift, which has previously been shown to be associated with 
inactivation of PIKfyve (Coronas et al., 2008).  It is possible that other signals in MDA-MB468 
cells keep PIKfyve in an inactive state, which cannot be activated by AKT.  Future work will be 
required to discriminate between these different possibilities. 
 One possible method for identifying signaling cross talk in different cell types in a time 
and dose (either drug or stimulant) dependent manner is through utilization of high through put 
systems.  Multiplexing approach using mass spectrometry is a suitable approach to quantitatively 
determine proteomic changes in multiple samples.  Modifications to the existing technology so 
that it can quantitatively compare phosphorylation events will certainly enable to us to perform 
non-biased high content signaling.  Combined with other high content analyses such as genomic 
and transcriptomic profiling, phospho-multiplexing would reveal signaling connections that we 
were not described before.  Because this technology is not currently available we utilized a 
reductive dimethylation approach to compare, in a pair wise fashion, the effect of EGF 
stimulation in two different cell lines engineered to express ERK2 D and ERK2 DEF mutants at 
two different time points following EGF stimulation.  Even our initial analyses revealed that 
there is differential regulation of ERK crosstalk to AKT and mTORC1 pathways induced by a 
single amino acid mutation in these cells.  It is also important to note ERK2 Glu320, which is in 
the ERK2 DEF binding pocket, is found to be mutated in an oral cancer cell line to Lys (Arvind 
et al., 2005).  Analysis of the genomic mutations in cancer using catalogue of somatic mutations 
in cancer (COSMIC) (Forbes et al., 2011), revealed that in total ERK2 D319N and ERK2 E320K 
mutations were detected three times out of 21 ERK2 mutations detected up to date.  Taken 
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together these findings suggest that understanding the signaling downstream of ERK2 docking 
domains may have clinical relevance to a group of patients. 
Crosstalk in Health and Disease 
 We found that AKT regulation of EGFR degradation can regulate signaling to EGFR 
signaling to ERK and RSK.  EGFR signaling to the PI3K-AKT and ERK-RSK pathways is 
regulated by endocytosis at multiple levels.  Blocking EGFR internalization by expressing EGFR 
mutants or dominant-negative Dynamin reduces ERK and AKT activation (Goh et al., 2010; 
Vieira et al., 1996).  In addition, the route of EGFR internalization determines signal duration.  
Clathrin-dependent EGFR endocytosis promotes receptor recycling and sustained AKT 
activation, whereas non-clathrin dependent EGFR endocytosis promotes transient AKT 
activation and EGFR degradation (Sigismund et al., 2008).  Once internalized, EGFR remains 
associated with the signaling adapter Grb2 in the early endosomes (Di Guglielmo et al., 1994).  
EGFR signaling from the endosomes is sufficient to induce DNA synthesis and activates ERK 
and AKT in HeLa cells and regulates apoptosis during zebra fish development (Pennock and 
Wang, 2003; Schenck et al., 2008; Zoncu et al., 2009).  EGFR signaling to the ERK pathway is 
also regulated at the late endosomes by the p14-MEK1-MP1 complex (Teis et al., 2006; Teis et 
al., 2002).   
Our finding that AKT regulates EGFR trafficking and degradation suggests AKT can 
regulate EGFR signaling by regulating EGFR trafficking.  AKT inhibition increases phospho-
EGFR Tyr1068 and phospho-ERK levels in MCF10A cells.  The AKT1 isoform negatively 
regulates ERK signaling in these cells via an unknown mechanism (Irie et al., 2005).  We show 
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that the AKT inhibitor-induced up-regulation of ERK activation requires active EGFR, 
consistent with AKT-facilitating EGFR degradation as a mechanism to reduce ERK signaling.  
Trafficking and degradation are important components of oncogenic RTK signaling.  
Mutant EGFRs that drive lung cancer proliferation degrade slower than wild type EGFRs, 
associate less with the ubiquitination machinery, and co-localize more with the markers of the 
recycling endosomes (Chung et al., 2009; Shtiegman et al., 2007).  Constitutively active c-Met 
mutants require receptor endocytosis to promote migration and in vivo transformation (Joffre et 
al., 2011).  Our data suggest that therapeutic targeting of AKT in settings where RTKs are 
hyperactive should be performed with caution, due to AKT’s ability to facilitate EGFR 
trafficking and degradation and inhibit ERK signaling.  Thus, inhibiting AKT signaling in these 
cells may actually promote tumorigenesis by reducing the cell’s ability to clear surface receptors 
and inducing continued RTK signaling from the endosomes.  Determining the contribution of the 
AKT-mediated feedback to multiple RTKs through activation of PIKfyve in the context of 
various cancer cell types will enhance our understanding of RTK biology and the intricate 
downstream signaling networks. 
In addition to cancer, AKT crosstalk to ERK may also be relevant to diabetes where AKT 
is chronically inhibited.  In the context of type 2 diabetes, the adipose tissue is unable to 
stimulate AKT activity in response to insulin.  Reduction in AKT activity leads to inefficient 
glucose uptake by the cells because AKT mediated GLUT4 translocation to the cell membrane is 
disrupted.  One mechanism that contributes to the cells’ inability to activate AKT in response to 
insulin is due to hyperphosphorylation of IRS proteins on serine residues, which prevent 
signaling from insulin receptor to PI3K.  Both S6K and ERK have been shown to phosphorylate 
IRS proteins.  It is possible that when AKT is inhibited, ERK is hyperactived through 
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accumulation of cellular RTKs because of disrupted RTK degradation.  Hyperactive ERK may 
then increase IRS phosphorylation to inhibit Insulin receptor signaling to PI3K.  This would then 
cause even further inhibition of AKT leading to more severe defects in glucose uptake by the 
cells.  Therefore, in type two diabetes, pharmacological inhibition of ERK may reduce IRS 
phosphorylation leading to reactivation of insulin-PI3K-AKT signaling axis and therefore 
allowing for proper glucose uptake and alleviated disease.  However, these hypotheses should be 
tested further. 
Our discovery of RSK mediated MEKK3 inhibition adds another level of complexity to 
the crosstalk between growth, stress and metabolic pathways.  MEK1-2, PI3K, AKT, mTORC1 
and EGFR inhibitors are all in clinical trials for treatment of cancers that show activation of these 
pathways.  However, we currently do not understand whether these inhibitors regulate different 
biological processes in tumor and normal cell lines.  Several lines of experimental and clinical 
evidence show that MEK1-2 inhibitors reduce survival and proliferation of tumor cells that are 
addicted to ERK signaling.  However, the long term effects drug treatments, such as deregulation 
of cytokine production by either the stroma or the tumor cells due to relief of RSK mediated 
feedback to MEKK3 needs to be tested.  Given that the immune system has critical functions in 
tumor maintenance, metastasis and clearance, it is necessary to investigate the role of RSK 
crosstalk to p38, ERK5 and possibly to NFkB signaling pathways through inhibition of MEKK3 
in the context of cancer biology. 
Finally, another context that the cytokine production plays an important role is in 
metabolic syndromes where chronic inflammation contributes to the severity of the disease.  If 
RSK regulation of MEKK3 alters cytokine production, it will be important understand what role 
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RSK activity or lack thereof plays in pathogenesis of metabolic syndromes such as obesity and 
type 2 diabetes. 
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Chapter 6 
MATERIALS AND METHODS 
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Cell culture and transfections 
Human Mammary Epithelial cells were immortalized, maintained and infected pBabeNeo 
EGFR retrovirus as previously described (Mendoza et al., 2011b).  For knockdown experiments 
cells were plated at a density of 200-250 thousand cells per 6 cm dishes 24 hours before 
transfection with  Allstars non-targeting control siRNA  (Qiagen) or siRNAs targeting AKT1, 
RAB11a, and ArPIKfyve, PIKfyve (Qiagen) or SAC3 (Dharmacon) using Lipofectamine 
RNAimax reagent (Invitrogen).  MCF10A cells were cultured as previously described (Irie et al., 
2005).  HEK 293T and 293E cells were cultured in DMEM containing 10% FBS.  Calcium 
phosphate transfections in HEK293 cells were done as previously described (Mendoza et al., 
2011b). 
List of siRNA target sequences 
 AKT1-1: aatcacaccacctgaccaaga 
 AKT1-2: cacgcttggtcccgaggccaa 
 RAB11-1: aagagtaatctcctgtctcga 
 RAB11-2: cgaaatgagtttaatctggaa 
 SAC3-1: gaacaaagatgggacagaa 
SAC3-2: gaagttatctgtgctgtga 
SAC3-3: gtagtgagccttatatgaa 
SAC3-4: tctataaggtcgaagatac 
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PIKFYVE: cagagatgagtatgcgctgta 
ArPIKfyve: ccggagggttgtcctctgaca 
Antibodies and reagents 
EGFR, pEGFR (Tyr1068), pAKT (Ser473), pS6K (Thr389), pPRAS40(Thr246), 
PRAS40, Ubiquitin, MEKK3, pAKT substrate antibody (110B7E) antibodies were from Cell 
Signaling Technologies.  Antibodies were from the following companies GAPDH (Ambion), 
FLAG tag, ppERK1/2 (Sigma), S-tag (Novagen), S6K1,  ERK and HA antibodies were made in 
house, EEA-1 (Santa Cruz Biotechnologies), Rab11 (BD biosciences).  EGFR antibody used for 
immuno-precipitation, immuno-fluorescence and flow cytometry (Calbiochem), ArPIKfyve and 
PIKfyve (Abcam).  Secondary Alexa-Fluor 488, 674 and 568 antibodies and Alexa-488 labeled 
EGF were purchased from Molecular Probes, Invitrogen.  Secondary antibodies for western 
blotting was from Li-COR.  Gefitinib (2μM final), PI103 (5μM final) and U0126 (20 μM Final), 
BI-D1870 (10μM final) and SL0-101(100μM final) was from Selleck Biochemical.  AKTVIII 
(10μM final) and YM201636 (200nM final) were from Calbiochem. All inhibitors were 
dissolved in dimethyl sulfoxide (DMSO) with the exception of SL0-101 which was dissolved in 
ethanol.  All inhibitors were stored as aliquots at -20oC with the exception of AKTVIII which 
was stored at -80oC. DMSO, N.E.M (N-ethylamimide), Cyclohexmide and Chloroquine was 
from Sigma-Aldrich. EGF, Insulin was from Pepro-Tech.  AKT catalytic inhibitor A-443656 was 
a kind gift from Dr. Nathaniel Gray. 
Cell Lysis, immuno-precipitation and western-blotting  
Cell lysis was performed as previously described in the presence of protease and 
phosphatase inhibitors (Mendoza et al., 2011b).  For ubiquitination experiments 10μM NEM was 
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added to the lysis buffer.  EGFR was immuno-precipitated with EGFR antibody or mouse IgG 
and with a 1:1 mixture of Protein A (Sigma-Aldrich) and Protein G Sephrose Beads (GE Health 
Care) at 4oC for 90 minutes.  FLAG PIKfyve was immuno-precipitated using agarose conjugated 
FLAG antibodies (Sigma, Aldrich).  HA-ArPIKfyve and HA-RSK were immunoprecipitated 
with anti HA antibody with Protein A.  Beads were spun at 5000rpm for 1 minute and the flow-
through was discarded.  Beads were washed three times with lysis buffer and boiled with SDS 
loading buffer at 100 0C for 6 minutes.  Western blotting and quantification using the Odyssey 
Li-COR imaging system was carried out as previously described (Mendoza et al., 2010). 
EGFR degradation assays 
 EGFR degradation assays were carried out by depriving cells of growth factors and or 
serum overnight and stimulating them with 100ng/mL EGF unless otherwise stated.  EGFR 
protein abundance at each time point before EGF stimulation (EGFR(0min)) and after EGF 
stimulation (EGFR(t) where t = 30min, 60min…) was measured by western blotting and 
quantification of the integrated intensity of EGFR bands with the Odyssey software (Li-COR).  
Percent undegraded EGFR was determined by calculated by the formula: EGFR(t)/EGFR(0min). 
Immuno fluorescence and image analysis 
Cells were plated on HCl treated coverslips as previously described (Mendoza et al., 
2011b) at a density of 50,000 cells per well in 6-well plates, 48 hours prior to assay.  Cells were 
deprived of growth factors 24 hours prior to staining and treated with inhibitors as indicated. 
Cells were fixed with 3.7% Formaldehyde and stained overnight with primary antibody for 
EEA.1 (1:100) and EGFR (1:100).  Images were taken using Nikon Ti inverted microscope with 
Yokagawa CSU-10 spinning disk confocal microscope at 60X magnification.  Images were taken 
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from the focal plane of the nucleus or as Z-stacks at a 0.3μm step size.  Percent co-localization 
values were calculated using the measure co-localization function of the MetaMorph®  software.  
Pixels with intensity values above a fixed threshold from each channel were used for 
calculations.  Statistical analysis of the percent co-localization values was carried out using 
bootstrapping permutation test (Efron and Tibshirani, 1993).  Box plots were generated using 
MATLAB ® (R2012a, Natick, MA).  For measurement of integrated intensities of EGF and 
EGFR in EEA.1 positive early endosomes, we created early endosomes from EEA.1 pixels that 
are above the local background and form a continuous shape with a fixed minimum and 
maximum size.  These endosomes were transferred over to the images that contain the 
EGF/EGFR signal and the EGF/EGFR signal only within these regions was calculated as 
integrated intensities after a constant background subtraction.  Integrated intensities from every 
other Z-plane were pooled for an entire field.  Integrated EGF-EGFR intensities in DMSO and 
AKTVIII treated cells were compared using Kolmogorov-Smirnov analysis for non-normal 
distributions.  Cumulative distribution function plots were generated using MATLAB ® . 
EGFR recycling assay 
EGFR recycling was assessed as previously described in (Sigismund et al., 2008) with 
the following changes.  3 plates of cells were pulsed with 100ng/mL EGF or TGFα for 15 
minutes at 37oC to allow for internalization and 1 plate was left un-stimulated (Total Surface 
EGFR).  Internalization was stopped by moving the cell to 4oC.  Excess EGF on cell surface was 
washed away with an acid treatment (150mM NaCl, 50mM Glycine at pH 3.0) for 3 minutes at 
4oC and washed with PBS three times.  One plate was left at 4 oC (Pulse).  Two plates were 
moved back to 37oC to allow for recycling for 10 or 20 minutes (Chase).  Following the chase 
period, cells were moved back to 4oC, fixed with 1% Formaldehyde in PBS, washed once with 
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PBS and twice with STE (10mM Tris-Cl, pH7.5, 10mM NaCl, 1mM EDTA) and collected.  Cell 
suspension was blocked with 3% BSA in PBS at 4oC for 30 minutes and labeled with EGFR 
antibody (1:100) at 4oC for one hour in 3% BSA and with Alexa-488 donkey anti mouse 
antibody for 30 minutes at 4oC.  Using flow-cytometry 10,000 cells were evaluated for surface 
EGFR staining.  Percent recycling at either 10 or 20 minute time points was calculated using the 
formula ((Chase – Pulse) /(Total Surface EGFR – Pulse)) * 100 from median values of each 
treatment group (Figure 6.1). 
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Figure 6.1 EGFR recycling assay 
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Phosphoinositide phosphatase assays. 
FLAG-PIKfyve, S-SAC3 and HA-ArPIKfyve complex was expressed in HEK293T cells.  
The complex was immunoprecipitated with anti-HA antibodies (30 minutes at 4oC) and Protein 
A beads (1 hour at 4oC).  Immunoprecipitates were washed twice with lysis buffer and twice 
with phosphatase buffer (50mM Tris-Cl pH7.4, 1mM MgCl2 , 1mM Dithiothreitol).  Beads were 
then resuspend with 35uL of reaction mixture (31uL of phosphatase buffer and 4uL of di-C8 
PI(3,5)P2 (Echelon-inc Biosciences).  Reactions were carried out at 37 C degrees for 15 minutes 
for WT SAC3 and for 60 minutes for D488A mutant.  25uL of the reaction was mixed with 
malachite green assay buffer (Echelon-inc Biosciences).  Amount of free phosphate liberated 
from PI(3,5)P2 via SAC3 activity in each reaction was read at 660nm along with free phosphate 
standards and calculated as instructed by the manufacturer. 
Phosphoinositide kinase assay 
PI3P (Avanti Polar Lipids) vesicles was generated by sonication for 10 minutes in 
HEPES (30mM pH 7.4) / EGTA (1mM) buffer.  FLAG-PIKfyve, S-SAC3 and HA-ArPIKfyve 
complex expressed in 293T cells was immunoprecipitated as above, washed twice with lysis 
buffer and twice with TNE buffer (20 mM Tris-HCl pH 7.4, 100 mM NaCl, 0.5mM EGTA). 
After the first wash 1/11th of the imunnoprecipated beads were used for western-blotting to 
ensure equal loading, the rest was used in the phosphoinositide kinase assay. After second wash 
the beads were resuspended in 65μL TNE buffer, incubated with PI3P vesicles for 5 minutes on 
ice and incubated with 10 μL ATP reaction mix (6.5 mM HEPES pH 7.4, 50µM ATP, 2.5mM 
MnCl2, 10mM MgCl2, 5mM β-glycerophosphate, 12.5µCi 32P-ATP final) for 15 minutes at room 
temperature.  Reaction was stopped by adding 4N HCl and phosphoinositides were extracted 
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using 1:1 Methanol:Chloroform.  Phosphoinositides were spotted on Silica TLC (Milipore) and 
separated using 65:35 2M Acetic acid:n-proponal.  Membrane was dried and exposed to 
Phospho-imager screen (Bio-Rad) and the radioactively labeled PI(3,5)P2 spots' volumes were 
quantified using Quantity One® software (Bio-Rad). 
Bacterial Protein Purification 
 GST-NIPA and GST-MKK3 were purified from bacterial cells as previously described 
(Mendoza et al., 2010).  Bacteria were transformed with the pGEX-2T GST-MKK3 or GST-
NIPA plasmids and plated antibiotic containing LB Agar plates containing 100µg/mL 
carbenicillin.  After overnight growth, single colonies were picked and grown overnight in 10mL 
of LB media with 100µg/mL carbenicillin at 37oC with constant shaking.  The starter cultures 
were then transferred into 1L of 2xYT media (BD biosciences) with 100µg/mL carbenicillin.  
OD600 was monitored and bacterial protein expression was induced with 0.2mM Dioxane-free 
isopropyl-beta-d-thiogalactopyranoside (IPTG) final when OD600 reached 0.8.  Induction was 
continued overnight at 16oC.  The bacterial pellets were homogenized in lysis buffer using a 
dounce homogenizer.  For GST-NIPA purification the lysis buffer was 1 × PBS, pH 7.4 with 50 
mM EDTA, pH 8.  For GST-MKK3 the lysis buffer was 20 mM Tris, pH 7.4, 150 mM NaCl, 5 
mM MgCl2 and 1% NP-40.  The resulting homogenates were passed through a pre-chilled 
microfluidizer at 20,000 PSI, twice.  The lysates were spun at 45.000rpm for 30min in an 
ultracentrifuge.  GST proteins in the supernatant were immune-precipitated with Glutathione 
Sepharose 4B beads (GE Healthcare) at 4oC for 1h.  GST beads were washed in a 
chromatography column using gravity.  GST proteins were eluted with lysis buffer with 10mM 
glutathione pH 7.5 and snap frozen in liquid nitrogen. 
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Protein kinase assays 
 Protein kinase assays using RSK as the kinase and GST-NIPA as the substrate was 
similar to described before (Mendoza et al., 2010).  HA-avRSK1 was immunoprecipitated from 
cells.  The immune-precipitates were washed twice in lysis buffer and twice in kinase buffer (25 
mM Tris base (pH 7.4), 1 mM DTT, 10 mM MgCl2, 2.5 mM b-glycerophosphate).  Kinase assay 
was performed in kinase buffer with 125µM ATP and 5µCi 32P-ATP for 15 minutes at 30 
degrees. 
 Protein kinase assays using MEKK3 as the kinase and GST-MKK3 was performed by 
lysing the HA-MEKK3 expressing cells using lysis buffer (20 mM Tris-Cl at pH 7.4, 1% NP-40, 
135 mM NaCl, 10% glycerol, 0.1 mM EDTA and 0.1mM EGTA).  HA-MEKK3 
immunoprecipitates were washed twice in lysis buffer and twice in kinase buffer.  MKK3 and 
MEKK3 was incubated in kinase buffer with 1mM DTT, 10mM beta-glycerophosphate 0.1mM 
sodium ortho vanadate, 125 µM ATP, 5µCi 32P-ATP for 12 minutes at 30 degrees.  
 The kinase reactions were stopped by adding 5X SDS loading buffer and boiling samples 
at 80oC.  The kinase reactions were resolved by SDS-PAGE and proteins were transferred onto 
membrane.  Incorporated radioactivity onto MEKK3, MKK3, RSK and NIPA was calculated by 
exposing the membrane to Phosphor-Imager (GE Healthcare) and quantifying radioactivity using 
Quantity One image software.  
Measurement phosphoinositides in cells 
HMECs are plated at 1 million cells per 10 cm plate and phosphoinositides were 
radioactively labeled by growing cells with inositol free DMEM/F-12 media (U.S. Biologicals) 
supplemented 10μCi/mL 3H-myo-inositol (American Radiolabeled Chemicals) for 48 hours 
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with.  Cells were then starved for growth factors by incubation in inositol free DMEM/F12 
media without EGF and Insulin for 1 hour.  Inhibitors were added at the last 30 minutes of 
starvation.  Cells were then stimulated with EGF (100ng/mL) for 30 min.  Phosphoinositides 
were then extracted, deactylated and seperated by HPLC as described previously (Sarkes and 
Rameh, 2010). 
Mass spectrometry analysis 
 Mass spectrometry was performed on MCF10A cells where endogenous ERK2 was 
knocked down and ERK2 D (Y261A) or ERK2 DEF (D319N) was re-expressed.  Cells were 
deprived of serum, EGF and insulin overnight and either stimulated with 10ng/mL EGF for 10 
minutes or 60 minutes or left unstimulated.   Cells were lysed with 8M urea and sonicated.  The 
supernatants were normalized for protein concentration.  5mg of protein lysate from each cell 
line and each treatment was denatured by adding DTT and heating to 56oC. Unreacted DTT was 
quenched, samples were trypsin digested.  Resulting peptides were desalted using tC18 SepPak 
solid-phase extraction cartridges and labeled using reductive dimethylation (Khidekel et al., 
2007). Following labeling peptides were run on strong cation exchange chromatography as 
previously described (Villen and Gygi, 2008).  Phospho-peptides were further enriched by 
titanium dioxide enrichment and were run on LC-MS/MS.  The resulting heavy to light ratios 
were generated as previously described (Villen and Gygi, 2008). 
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